CLINICAL STUDY PROTOCOL
Study Title: A Phase 1, Open- Label, Multiple Dose Study  to Evaluate the 
Pharmacokinetics of Entospletinib in Subjects with Normal and 
Impaired Hepatic Function
Sponsor: Gilead Sciences, Inc.
333 L akeside Drive
Foster City , CA 94404
IND No.:
EudraCT Number:
ClinicalTrials.gov 
Identifier:116416
Not Applicable
TBD
Indication: Oncology
Protocol ID: GS-US-339-1631
Gilead Sciences Medical 
MonitorName:
Telephone:
Fax:
Mobile :
Protocol Version/Date: Original: 28July 2015
CONFIDENTIALITY STAT EMENT
The information contained in this document, particularly  unpublished data, is the propert y or 
under control of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, 
potential investigator, or consultant, for review b y you, your staff, and an applicable Institutional 
Review Board or Independent Ethics Committee. The information is only  to be used by  you in 
connection with authorized clinical studies of the investigational drug described in the protocol.
You will not disclose any of the information to others without written au thorization from 
Gilead Sciences, Inc., except to the extent necessary  to obtain informed consent from those 
persons to whom the drug may  be administered.
PPD
PPD
PPD
PPD
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 2 28 July 2015TABLE OF CONTENTS
TABLE OF CONTENTS .............................................................................................................................................. 2
LIST OF IN- TEXT TABLES ........................................................................................................................................ 4
LIST OF IN- TEXT FIGURES ...................................................................................................................................... 4
PROTOCOL SYNOPSIS .............................................................................................................................................. 5
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 11
1. INTRODUCTION .............................................................................................................................................. 14
1.1. Background ............................................................................................................................................ 14
1.2. Entospletinib (ENTO, GS -9973)............................................................................................................ 14
1.2.1. General Information ............................................................................................................. 14
1.2.2. Preclinical Pharmacology and Toxicology ........................................................................... 14
1.2.3. Clinical Trials of Entospletinib ............................................................................................ 15
1.3. Rationale for the Current Study ............................................................................................................. 16
1.3.1. Rationale for the Dose Selection .......................................................................................... 17
1.4. Com pliance ................................
............................................................................................................ 17
2. OBJECTIVES ..................................................................................................................................................... 18
3. STUDY DESIGN ................................................................................................................................................ 19
3.1. Study Design .......................................................................................................................................... 19
3.2. Study Drug Administration .................................................................................................................... 21
3.3. Clinic Confinement ................................................................................................................................ 21
3.4. Pharm acokinetic Assessments ................................................................................................................ 21
3.4.1. Plasma Pharmacokinetic Collection ..................................................................................... 22
3.5. Safety Assessments ................................................................................................................................ 22
3.6. Genetic Testing ...................................................................................................................................... 22
4. SUBJECT POPULATION .................................................................................................................................. 23
4.1. Number of Subjects and Subject Selection ............................................................................................ 23
4.2. Inclusion Criteria .................................................................................................................................... 23
4.2.1. All Subjects (Healthy Control Subjects and Subjects with Hepatic 
Impairm ent).......................................................................................................................... 23
4.2.2. Subjects with Impaired Hepatic Function ............................................................................ 24
4.2.3. Healthy Matched Controlled Subjects .................................................................................. 25
4.3. Exclusion Criteria ................................................................................................................................... 26
4.3.1. All Subjects .......................................................................................................................... 26
4.3.2. Subjects with Impaired Hepatic Function ............................................................................ 28
4.3.3. Healthy Matched Controlled Subjects .................................................................................. 28
5. STUDY DRUGS ................................................................................................................................................. 29
5.1. Randomization and Blinding .................................................................................................................. 29
5.2. Description and Handling of Entospletinib ............................................................................................ 29
5.2.1. Form ulation .......................................................................................................................... 29
5.2.2. Packaging and Labeling ....................................................................................................... 29
5.2.3. Storage and Handling ........................................................................................................... 30
5.3. Dosage and Administration of Study Drug ............................................................................................ 30
5.4. Fasting and Meals .................................................................................................................................. 30
5.5. Dispensing, Accountability, and Disposal or Return of Study Drug ...................................................... 31
5.6. Concomitant Medications and Other Protocol Restrictions ................................................................... 31
5.6.1. Concomitant Medications ..................................................................................................... 31
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 3 28 July 20155.6.2. Other Protocol Restrictions .................................................................................................. 32
6. STUDY PROCEDURES .................................................................................................................................... 33
6.1. Subject Enrollment and Treatment Assignment ..................................................................................... 33
6.2. Pretreatment Assessments ...................................................................................................................... 36
6.2.1. Screening Visit ..................................................................................................................... 36
6.2.2. Admission Assessments ....................................................................................................... 36
6.3. Check -In Assessments ........................................................................................................................... 37
6.4. Treatment Assessments .......................................................................................................................... 37
6.5. Posttreatment Assessments .................................................................................................................... 37
6.6. Assessments for Premature Discontinuation from Study ....................................................................... 37
6.7. Criteria for Discontinuation of Study Drug ............................................................................................ 38
6.8. Pharm acokinetic Assessments ................................................................................................................ 38
6.8.1. Plasma PK Collection ........................................................................................................... 38
6.9. Safety Assessments ................................................................................................................................ 38
6.9.1. Electrocardiogram Assessment ............................................................................................ 38
6.9.2. Physical Examination ........................................................................................................... 39
6.9.3. Vital Signs ............................................................................................................................ 39
6.9.4. Body  Mass Index .................................................................................................................. 39
6.9.5. Clinical Laboratory Tests/Assessments ...............................................................
................. 39
6.9.6. Creatinine Clearance ............................................................................................................ 40
6.9.7. Adverse Events/Concomitant Medications/Protoc ol Restrictions ........................................ 40
6.10. Genetic Testing ...................................................................................................................................... 40
6.11. Sample Storage ....................................................................................................................................... 41
7. ADVERSE EVENTS AND T OXICITY MANAGEMENT ............................................................................... 42
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events ................................. 42
7.1.1. Adverse Events ..................................................................................................................... 42
7.1.2. Serious Adverse Events ........................................................................................................ 42
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events ......................................................................... 43
7.2. Assessment of Adverse Events and Serious Adverse Events ................................................................. 43
7.2.1. Assessment of Causality for Study Drugs and Procedures ................................................... 43
7.2.2. Assessment of Severity ........................................................................................................ 44
7.3. Investigator Requirements and Instructions for Reporting Adverse Events and Serious 
Adverse Events to Gilead ....................................................................................................................... 44
7.3.1. Requirements for collection prior to study drug initiation: .................................................. 44
7.4. Gilead Reporting Requirements ............................................................................................................. 46
7.5. Clinical Laboratory Abnormalities and Other Abnormal Assessments as Adverse Events or 
Serious Adverse Events ................................................................
.......................................................... 46
7.6. Toxicity Management ............................................................................................................................ 47
7.7. Special Situations Reports ...................................................................................................................... 47
7.7.1. Definitions of Special Situations .......................................................................................... 47
7.7.2. Instructions for Reporting Special Situations ....................................................................... 48
8. STATISTICAL CONSIDER ATIONS ................................................................................................................ 50
8.1. Analysis Objectives and Endpoints ........................................................................................................ 50
8.1.1. Analysis Objectives .............................................................................................................. 50
8.1.2. Primary Endpoint ................................................................................................................. 50
8.1.3. Secondary Endpoint ............................................................................................................. 50
8.2. Analysis Conventions ............................................................................................................................. 50
8.2.1. Analysis Sets ........................................................................................................................ 50
8.3. Data Handling Conventions ................................................................................................................... 50
8.4. Dem ographic Data and Baseline Characteristics ................................................................................... 51
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 4 28 July 20158.5. Safety Analysis ....................................................................................................................................... 51
8.5.1. Extent of Exposure ............................................................................................................... 51
8.5.2. Adverse Events ..................................................................................................................... 51
8.5.3. Laboratory Evaluati ons........................................................................................................ 51
8.5.4. Other Safety Evaluations ...................................................................................................... 52
8.6. Pharm acokinetic Analysis ...................................................................................................................... 52
8.7. Sample Size ............................................................................................................................................ 52
9. RESPONSIBILITIES .......................................................................................................................................... 53
9.1. Investigator Responsibilities ................................
.................................................................................. 53
9.1.1. Good Clinical Practice .......................................................................................................... 53
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (EC) 
Revie w and Approval ........................................................................................................... 53
9.1.3. Informed Consent ................................................................................................................. 53
9.1.4. Confidentiality ...................................................................................................................... 54
9.1.5. Study Files and Retention of Records .................................................................................. 54
9.1.6. Case Report Forms ............................................................................................................... 55
9.1.7. Study Drug Accountability and Return ................................................................................ 56
9.1.8. Inspections ............................................................................................................................ 56
9.1.9. Protocol Compliance ............................................................................................................ 56
9.2. Sponsor Responsibilities ........................................................................................................................ 56
9.2.1. Protocol Modifications ......................................................................................................... 56
9.2.2. Study Report ......................................................................................................................... 57
9.3. Joint Investigator/Sponsor Responsibilities ........................................................................................... 57
9.3.1. Payment Reporting ............................................................................................................... 57
9.3.2. Access to Information for Monitoring .................................................................................. 57
9.3.3. Access to Information for Auditing or Inspections .............................................................. 57
9.3.4. Study Discontinuation .......................................................................................................... 57
10. REFERENCES ................................................................................................................................................... 58
11. APPENDICES .................................................................................................................................................... 59
Appendix 1. Investigator Signature Page .................................................................................................... 60
Appendix 2. Management of Clinical and Laboratory Adverse Events ...................................................... 61
Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................... 62
Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities ............... 65
Appendix 5. Child -Pugh -Turcotte Score .................................................................................................... 85
LIST OF IN -TEXT TABLES
Table 6-1. Schedule of Assessments –All Cohorts ................................................................................. 34
LIST OF IN -TEXT FIGURES
Figure 3-1. High Level Study Schema ...................................................................................................... 20
Figure 3-2. Study Schema –All Cohorts .................................................................................................. 21
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 5 28 July 2015PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
StudyTitle: A Phase 1, Open- Label, Multiple Dose Study  to Evaluate the 
Pharmacokinetics of Entospletinib in Subjects with Normal and 
Impaired Hepatic Function
IND Number:
EudraCT Number:116416
Not Applicable
Study Centers 
Planned:Multiple centers in the United States and New Zealand
Objectives: The primary objective of this study  isas follows:
To evaluate the pharmacokinetics of Entospletinib (ENTO) and/or 
its metabolites (if applicable) in subjects with impaired hepatic 
function relative to matched, health y controls
The secondary  objective of this study  is as follows:
To evaluate the safet y and tolerability  of administration of ENTO 
in subjects with normal and impaired hepatic function
Study Design: Phase 1, open -label, parallel -group, adaptive , multiple dose study
Number of Subjects 
Planned:A minimum of 20 subjects and a maximum of 60 subjects total. 
Cohort 1 (Moderate Hepatic Impairment) initial cohort
Up to 20 subjects: 10 with moderate impairment, 10 matched healthy  
controls, for 8 evaluable subjects per group 
Adaptive Cohort 2 (Severe Hepatic Impairment) 
Up to 20 subjects: 10 with severe impairment, up to 10 matched 
healthy  controls, for 8 evaluable subjects per group. Data from 
healthy  subjects in previous cohort who are an appropriate match for 
a severe impairment subject may  be used.
Adaptive Cohort 3 (Mild Hepatic Impairment)
Up to 20 subjects: 10 with mild impairment, up to 10 matched healthy 
controls, for 8 evaluable subjects per group. Data from health y 
subjects in previous cohort who are an appropriate match for a mild 
impairment subject may  be used.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 6 28 July 2015The 90% CIs will be examined to determine if a meaningful change 
(≥ 2-fold mean difference fro m matched controls) in the exposures of 
ENTO and/or metabolite (if applicable) is identified which would be 
clinically  interpreted . A decision to enroll s ubjects in adaptive 
Cohort 2 (Severe Hepatic I mpairment) and/or adaptive Cohort 3 
(Mild Hepatic Impairment) will be enrolled as determined b y safety
(treatment -emergent AEs, treatment- emergent laboratory  
abnormalities, vital signs, safet y ECGs) and/or PK data from 
Cohort 1 (Moderate Hepatic I mpairment). Specifically , Cohort 2 will 
beinitiated if su pported by  safety (treatment -emergent AEs, 
treatment -emergent laboratory  abnormalities, vital signs, safety  
ECGs) 
and PK findings from subjects in Cohort 1. Cohort 3 will be 
enrolled if a clinically meaningful change ( ≥ 2-fold mean difference 
from matched healthy  controls) in the exposures of ENTO and/or 
metabolite (if applicable) exposure is identified in Cohort 1 .
Target Population: Male and non- pregnant, non -lactating females subjects aged
≥ 18 years, with vary ing degrees of hepatic impairment and matched 
healthy  controls. Those with hepatic impairment will be categorized 
based upon the Child- Pugh -Turcotte (CPT) classification sy stem for 
hepatic impairment (CPT Class A, B, or C) as recommended by the 
United States Food and Drug Administration (FDA) and i nternational 
guidance documents. Within the CPT system, subjects will be 
assigned to Class A, B, or C based on a cumulative score evaluating 
the presence and severity of hyperbilirubinemia, hypoalbuminemia, 
prolongation of international normalized ratio (I NR) for coagulation 
time, ascites, and hepatic encephalopath y. Designations of hepatic 
impairment will be assigned as follows:
Class A (mild): CPT score 5-6
Class B (moderate): CPT score 7 -9
Class C (severe): CPT score 10 -15
The control group will consist of matched health y subjects with 
normal hepatic function.
Duration of Dosing: 5 day s 
Study  Duration: 20 day s 
Main Eligibility  
Criteria:Eligible subjects will be male and non -pregnant, non -lactating female 
subjects, aged ≥ 18 years, 18 BMI 40, with either impaired 
hepatic function of CPT classification A, B, or C or with normal 
hepatic function. Hepatic impairment must have been stable during 
the 3 months (90 day s) prior to study  drug administration. 
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 7 28 July 2015Each subject in the control group will be matched to a subject with 
impaired hepatic function by  age (± 10 y ears), gender, and body  mass 
index (± 20%). 
Subjects with use of strong CYP3A4 inhibitors /CYP3A4 inducers, 
and strong CYP2C9 inhibitors /inducers within 2 weeks prior to stud y 
drug administration will be excluded since these agents may  affect the 
PK of ENTO .
Study  Procedures/
Frequency :Following completion of Screening and Day  -1 assessments, eligible 
subjects will be enrolled in Cohort 1 (followed by  Cohorts 2 and/or 3 
pending PK/Safety  review) and receive multiple doses of 100 mg 
twice dail y (BID) ENTO (1 
00 mg tablet) starting on Day 1.
When feasible, dosing in a matched control subject with normal 
hepatic function will occur after the  subject with impaired hepat ic 
function has completed the PK assessments, except if data exist from 
a subject with normal hepatic function in a previous cohort, this will 
be used instead of enrolling an additional normal healthy  control 
subject as permitted in adaptive Cohorts 2 and 3.
Subjects in adaptive Cohort 2 (Severe Hepatic Impairment) and/or 
adaptive Cohort 3 (Mild Hepatic Impairment) will be enrolled as 
determined b y safet y and/or PK data from Cohort 1 (Moderate 
Hepatic Impairment). Specificall y, Cohort 2 will be initiated if
supported by  safet y and PK findings from subjects in Cohort 1. 
Cohort 3 will be enrolled if a clinicall y meaningful change ( ≥ 2-fold 
mean difference from matched health y controls) in the exposures of 
ENTO and/or metabolite (if applicable) exposure is iden tified in 
Cohort 1. (Refer to Section 8.7, Sample Size)
Study Visits and Confinement
Eligible subjects will be confined to the stud y center beginning
Day -1 until the completion of assessments on Day  9. Subjects will 
return for an in -clinic follow -up visit 14 (±1) day s after the last dose 
of study  drug (i.e., Day  19).
Study Drug Administration
All study  treatments will be administered at approximately  the same 
time each day  with 240 mL  of water following an overnight fast 
(nofood or drinks except water, fo r at least 8 hours).
When ENTO is administered twice a day , the evening dose of ENTO 
will be administered approximately  12 hours after the AM dose. 
Subjects should continue fasting for 2 hours post AM dose and 
2hours before and 2 hours after the PM dose.
Only  the AM dose of ENTO will be given on Day  5.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 8 28 July 2015On the day s of intensive pharmacokinetic sampling, study treatments 
will be administered in the morning following an overnight fast 
(nofood or drinks except water, for at least 8 hours). Subjects will
conti nue to fast until after collection of the 4 -hour pharmacokinetic 
samples, relative to stud y drug dosing.
Additionally , subjects will be restricted from water consumption
1 hour before until 2 hours after dosing, except for the 240 mL  given 
with the study  treatment.
Pharmacokinetic Assessments
Serial blood samples will be collected relative to the AM dose on the 
following day s and timepoints for ENTO and/or metabolites 
(ifapplicable).
Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (pre-PM dose)
hours postdose
Day 5: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 
84, and 96 hours postdose
Trough Sampling: Day s 2 and 4: 0 (pre -AM dose, at approximately  
the same time each day )
Plasma concentrations for ENTO and/or its metabolites (if applicable) 
will be determined and PK parameters evaluated. Protein binding of 
ENTO and/or its metabolites (if applicable), may  be assessed at their 
Tmaxtime point(s) as well as another later time point.
An additional Trough PK sample will be collecte d at the follow -up 
visit for assessing p lasma concentrations for ENTO and/or its 
metabolites (if applicable) .
Safety Assessments
Complete physical exam: Screening and at the follow -up visit or the 
Early Termination visit (if applicable)
Symptom driven physical exam: Day -1, Day  3, Day  7, and prior to
discharge on Day  9
Vital signs (blood pressure, pulse, respiration rate, and temperature):
Screening, Day  -1, Day 3, Day  7, prior to discharge on Day  9, at the 
follow -up visit, and at the earl y termination v isit, if applicable.
Clinical laboratory tests (hematology, blood chemistry, and 
urinalysis):   
Screening, Day  -1, Day  7, prior to discharge on Day  9, at 
the follow-up visit, and at the earl y termination visit, if applicable.
Urine Drug and Alcohol Assessme nts:Screening, Day  -1, Day  5, 
prior to discharge on Day 9, at the follow-up visit, and at the earl y 
termination visit, if applicable.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 9 28 July 201512-lead ECG: Screening, Day  -1, Day 3, Day  7, prior to discharge on 
Day 9, at the follow -up visit, and at the earl y termination visit, if 
applicable.
Serum Pregnancy Test (women of childbearing potential only):
Screening, Day  -
1, Day  4,prior to discharge on Day  9, at the 
follow -up visit, and at the earl y termination visit, if applicable.
Serology Test (HBV, HCV, HIV): Screening
FSH testing (females of childbearing potential only): Screening
OtherAssessments
Height: Screening
Weight: Screening, Day  -1
Assessment of adverse events and concomitant medications will 
continue throughout the study . 
Genetic Testing
A separate , mandatory  blood specimen will be collected for the 
extraction of deox yribonucleic acid (DNA) for genoty ping to identify  
polymorphisms of drug metabolizing enzy mes (such as CYP2C9, 
CYP3A4/5, CYP1A2 and UGT1A1) and transporters (such as 
OATP 1B1/3, P -gp, BCRP and MATE1) to optimize the therapeutic 
strategy  for ENTO. This sample should be collected on Day  -1, 
before administration of the first dose of stud y drug, but may be 
collected at an y time during clinic confinement.
Test Product, Dose, 
and Mode of 
Administration:ENTO 100 mg [1 100 mg tablet] twice a day
Reference Therapy, 
Dose, and Mode of 
Administration:Not applicable
Criteria for 
Evaluation:
Safety : Safety  will be evaluated by  assessment of periodic phy sical
examinations including vital sign and 12 -lead ECGs performed at
various time points during the stud y, by the documentation of adverse 
events, and b y intervention with concomitant medications.
Efficacy : Not applicable
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 10 28 July 2015Pharmacokinetics: The following plasma pharmacokin etic parameters will be calculated: 
Cmax, Tmax, Clast, Tlast, z, AUC last, AUC inf, %AUC exp, T½, CL/F, and 
Vz/F, and as appropriate, AUC tau, Ctau.
Statistical Methods: Pharmacokinetic parameters for ENTO and/or its metabolites
(ifapplicable) will be listed and summarized by  hepatic function 
group (normal or CPT Class A, B, or C) using descriptive statistics 
(e.g., sample size, arithmetic mean, geometric mean, % coefficient of 
variation, standard deviation, median, minimum, an maximum). An 
analysis of variance appropriate for a parallel design will be fit to the 
natural logarithm -transformed pharmacokinetic parameters (AUC and 
Cmax). The 90% confidence intervals (CIs) will be constructed for the 
least-squares geometric mean (GLS M) ratios of pharmacokinetic 
parameters for ENTO and/or its metabolite (if applicable), in groups 
of subjects with hepatic impairment versus the appropriate group of 
matched controls.
Protein binding of ENTO and/or its metabolites (if applicable) at their 
Tmaxand another later time point will be summarized by  hepatic 
function group using descriptive statistics (if applicable).
Safety  data will be listed by  subject and summarized by  hepatic 
function groups, and frequency  of event/abnormality  or descriptive 
statistical summaries, as appropriate.
A sample size of 8 evaluable subjects per group will provide a ≥ 89% 
probability  for the 90% CI  for the GLSM ratio of pharmacokinetic
parameters (AUC or C max) for ENTO in the hepatic 
impairment/dy sfunction group(s) ve rsus the appropriate group of 
matched controls, to be within limits of 50% to 200% . The 
calculation assumes an expected ratio of geometric means of 1.0 in 
pharmacokinetic parameters and inter -subject standard deviation of 
0.455 for the natural logarithm -transformed pharmacokinetic 
parameters for ENTO. The assumption is based on the data obtained 
from a prior clinical study of ENTO (Stud y GS -US-339- 0111).
This study  will be conducted in accordance with the guidelines of Good Clinical Practices 
(GCPs) incl uding archiving of essential documents.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 11 28 July 2015GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
C degrees Celsius
F degrees Fahrenheit
AE adverse event
ALL acute lymphoid leukemia
AML acute myeloid leukemia
ALT alanine aminotransferase
ANOVA analysis of variance
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
AUC area under the ENTO concentration versus time curve
AUC 0-last area under the plasma concentration -time curve from time 0 to the last 
measurable concentration
AUC inf area under the plasma/serum/PBMC concentration versus time curve 
extrapolated to infinite time, calculated as AUC 0-last+ (Clast/λ z)
AUC tau area under the plasma/serum/PBMC concentration versus time curve over the 
dosing interval
BID twice a day
BLQ below  limit of quantification
BMI body mass index
BUN blood urea nitrogen
CBC complete blood count
CFR Code of Federal Regulations
CI confidence interval
CK creatine kinase
CLL chronic lymphocytic leuke mia
CL/F apparent oral clearance
Clast last observed quantifiable serum/plasma/PBMC concentration of the drug
Cmax maximum observed ENTO concentration of drug
CPK creatine phosphokinase
CPT Child- Pugh -Turcotte
CrCl creatinine clearance
CRF case report form(s)
CRO contract (or clinical) research organization 
CSR clinical study report
CTA clinical trial application
Ctau observed drug concentration at the end of the dosing interval
CV coefficient of variation
DNA deoxyribonucleic acid
DSPH Drug Safety and Public Health
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 12 28 July 2015EC ethics committee
ECG electrocardiogram
eCRF electronic case report form(s)
EDC electronic data capture
ENTO entospetenib
eSAE electronic serious adverse event
ET early termination
EU European Union
FDA (United States) Food and Drug Administration
FSH follicle stimulating h ormone
FU follow  up
GCP Good Clinical Practice (Guidelines)
Gilead Gilead Sciences, Inc.
GLSM geometric least square mean
HBV hepatitis B virus
HCV hepatitis C virus
HDPE high density polyethylene
HIV human immunodeficiency virus
HLGT high-level group term
HLT high-level term
IB investigator’s brochure
ICF Informed Consent Form
ICH International Conference on Harmonisation
ID Identification
IND Investigational New Drug (Application)
INR international normalized ratio
IRB institutional review board
IUD intrauterine device
LLT lower-level term
LLOQ lower-limit of quantitation
LOEL lowest observable effect level
MedDRA Medical Dictionary for Regulatory Activities
NDA New  Drug Application
NHL non-Hodgkin lymphoma
NOEL no observable effect level
OTC over the counter
PD pharmacodynamics
PI principal investigator
PI3K phosphatidylinositol 3 -kinase
PK pharmacokinetic(s)
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 13 28 July 2015PT preferred term
PT prothrombin time
Q1 first quartile
Q3 third quartile
QT electrocardiographic interval betw een the beginning of the Q w ave and 
termination of the T w ave representing the time for both ventricular 
depolarization and repolarization to occur
QTcF QT interval corrected for heart rate using the Fridericia formulatio n
RA rheumatoid arthritis
SADR serious adverse drug reaction
SAE serious adverse event 
SAP Statistical Analysis Plan
SD standard deviation
SOC System  Organ Class
SOP standard operating procedure
SUSAR Suspected Unexpected Serious Adverse Reaction
SYK spleen tyrosine kinase
TEAE treatment -emergent adverse event
Tlast time (observed time point) of C last
Tmax the time (observed time point) of C max
T1/2 an estimate of the terminal elimination half -life of the drug in ENTO calculated 
by dividing the natural log of 2 by the terminal elimination rate constant (λ z)
US United States
Vz/F apparent volume of distribution of the drug
λz terminal elimination rate constant; estimated by linear regression of the terminal 
eliminati on phase of the log serum/plasma/PBMC concentration versus time 
curve of the drug
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 14 28 July 20151. INTRODUCTION
1.1. Background
Spleen ty rosine kinase (SYK) is a non -receptor cy toplasmic ty rosine kinase that is primarily  
expressed in cells of hematopoietic lineage and is an important mediator of immunoreceptor 
signaling in macrophages, neutrophils, mast cells, and B cells. SYK contains 2 adjacent Src 
Homology  2 (SH2) domains that bind to immunoreceptor t yrosine -based activation motifs 
(ITAMs) to autophosphory late and activate the enzy me. This allows SYK to phosphory late its 
specific substrates, including other enzy mes and adaptor proteins, orchestrating a complex series 
of cellular responses such as cell proliferation, differentiation, survival, and phagocy tosis in 
these cells.
Recent studies have suggested a role for the d ysregulation of SYK in B -cell malignancies. SYK 
is expressed in B cells and is essentially  involved in multiple signal transduction pathway s 
downstream of the B -cell receptor (BCR). In this process, SYK trans -autophosphory lates and 
activates effector molecules such as phospholipase C gamma (PLCγ), phosphatidy linositol 
3-kinase (PI3K), and mitogen -activated protein kinase (MAPK), and their associated signaling 
pathway s, to induce an array  of B -cell responses, i ncluding: proliferation, survival, 
differentiation, and apoptosis. I nhibition of BCR -mediated SYK activit y is therefore an attractive 
therapeutic target for hematopoietic B-cell malignancies where SYK inhibition could inhibit the 
proliferation and survival of malignant B cells.
1.2. Entospletinib (ENTO, GS -
9973)
The generic name of GS -9973 is entospletinib (ENTO).    
1.2.1. General Information
Entospletinib (ENTO) is a potent and highly  selective inhibitor of SYK, orally  bioavailable and 
is being developed for the treatment of hematologic malignancies. Entospletinib is currently  in a 
Phase 2 clinical trial in subjects with AML /ALL/CLL/NHL.
Further information is av ailable in the Investigator’s Brochure (IB) for GS -9973.
1.2.2. Preclinical Pharmacology and Toxicology
ENTO was evaluated in a standard battery  of safety  pharmacology  studies to assess potential 
effects on central nervous, cardiovascular, and respiratory  systems . ENTO had no effect on 
central nervous and respiratory  system parameters evaluated in rats. In a cardiovascular safet y 
pharmacology  study  in dogs, small increases in heart rate (up to a 25% increase) were observed 
in male dogs given ENTO at 15, 50, or 150 mg/kg. While the higher heart rates were considered 
ENTO -related, the relevance of these changes to humans is not known. Due to the observed 
increases in heart rate, a NOEL was not identified and t he lowest observed effect level (LOEL) 
was 15 -mg/kg. ENTO had no effect on ECGs or arterial blood pressure values at oral doses up to 
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 15 28 July 2015150 mg/kg, the highest dose tested. Consistent with the lack of effect on ECG parameters, ENTO
has no meaningful effect on the human -ether -a-go-go related gene (hERG), indicating t hat 
ENTO would not be expected to induce clinical QT prolongation. 
The toxicity  ofENTO has been characterized in animal genotoxicity , embry o-fetal reproductive 
toxicity , and phototoxicity  studies. Recently  published data demonstrated that species -specifi c GI 
toxicity  and l ymphoid changes, similar to that which was observed following ENTO
administration to dogs, can occur in dogs but not rats, cy nomolgus monkeys, or humans treated 
with p38 map kinase and MAP kinase activated protein kinase -2 (MK2 )small mo lecule kinase 
inhibitors that inhibit pathway s that overlap with SYK signaling pathway s {17647} . Oral 
administration of ENTO to rats for up to 26 weeks or cynomolgus monkey s for up to 39 weeks 
show ed no evidence of GI toxicity  or lymphoid changes at exposures which overlapped with or 
exceeded those that resulted in acute toxicity  in dogs. Furthermore, ENTO has been previously  
investigated in healthy  human subjects at doses up to 1200 mg twice a day for 7 day s and in 
subjects with RA at doses up to 900 mg  for 26 days and no evidence of GI or ly mphoid toxicity  
was observed in these clinical studies. Therefore, the relevance of these findings to humans is not 
known.
ENTO inhibits uridine disphosphate g lucuronos yltransferase 1A1 (UGT1A1) with an IC 50 of 
2μM. This enzy me is involved in glucuronidation of bilirubin, and inhibitors of UGT1A1 have 
the potential to produce increased levels of total and indirect (unconjugated) bilirubin in the 
circulation {8443} . 
ENTO is considered non- genotoxic and administration of ENTO did not result in skin reactions 
indicative of phototoxicity in mice.
Administration of ENTO to pregnant female rats and rabbits from implantation to the closure of 
the hard palate (Internati onal Conference on Harmoni sation [I CH] Harmonised Tripartite 
Guideline stages C to D) resulted in dose- dependent developmental findings including increased 
incidence of early  and late fetal resorptions and reduced fetal weights, and delay s in ossification 
of the forelimb phalanges (rats and rabbits) and metacarpals (rabbits only ). These fetal findings 
occurred at ENTO doses that caused maternal toxicity  as demonstrated in both studies by  
dose-dependent decreases in body  weight gain and/or body  weight loss a nd decreased food 
consumption of the dams. Maternal toxicity  was also demonstrated in these studies at doses that 
did not result in developmental findings.
1.2.3. Clinical Trials of Entospletinib
Positive results have been reported from a Phase 2 clinical trial with the putative SYK inhibitor 
fostamatinib showing objective anti -tumor responses in CLL and NHL subjects. {22804} These 
responses occurred despite off target toxicities that limited drug exposure. Entospletinib is a 
highl y selective inhibitor of SYK and hence has the potential for an improved efficacy and 
tolerability  profile in subjects with hematologic malignancie s.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 16 28 July 2015To date, 8 clinical studies have been initiated with ENTO including a total of 486 subjects 
(including 304 healthy  subjects, 7 subjects with rheumatoid arthritis (RA), 80 subjects with 
chronic l ymphocy tic leuke mia (CLL), 95 subjects with non- Hodgkins l ymphoma (NHL) ; 
26subjects receiving placebo) in Phase 1 and Phase 2 clinical studies. Of the 460 subjects 
receiving ENTO in these studies, ENTO has generally  been well tolerated.
Entospletinib is being evaluated in an ongoing Phase 2 clinical trial in subj ects with relapsed or 
refractory  CLL/NHL , and a Phase 1b/2 clinical trial in subjects with e ntospletinib monotherapy  
and in c ombination with chemotherap y in subjects with AML  and ALL.
ENTO given at doses up to 1200 mg twice a day (2400 mg/day ) for 7 day s was well tolerated in 
healthy  human subjects, and doses of up to 900 mg twice a day (1800 mg/day) given in 
combination with methotrexate were well tolerated for 26 day s in subjects with RA and at 
800mg BID (1600 mg/day ) was well tolerated in subjects with relapsed or refractory  CLL/NHL 
for a median duration of exposure for 15 weeks. 
Treatment emergent adverse events (AEs) that were commonly  reported across the studies 
included headache, somnolence, and GI s ymptoms (nausea and abd ominal pain), all of which 
were mild and reversible. ENTO administered for 26 day s at a dose of 900 mg twice a day was 
well tolerated b y subjects with RA on stable doses of methotrexate. This dose and treatment 
schedule produced levels of drug exposure similar to what we expect in subjects with 
hematologic malignancies receiving doses of ENTO at 800 mg twice a day .
Increased transaminases were noted in some su bjects observed approximately  2 weeks after 
completion of study  drug. I n the cohort of subjects wit h RA, 2 subjects had elevated 
transaminases, which were also observed after completion of study  drug. One subject with RA 
had elevated AST/ALT concurrent with bronchopneumonia while the other was diagnosed with 
acute hepatitis.
ENTO is expected to produce as ymptomatic and transient elevations of unconjugated (indirect) 
bilirubin due to inhibition of UGT1A1. Eight of 178 healthy  subjects treated developed 
asymptomatic indirect bilirubin elevations (6 Grade 1, 1 Grade 2, and 1 Grade 3) that resolved 
following discontinuation of the drug. Three of 7 subjects with RA who received ENTO for 
26days developed as ymptomatic indirect bilirubin elevations (2 Grade 1 and 1 Grade 3) which 
improved despite continued dosing.
Common AEs from an on -going Phase 2 stud y evalua ting chronic administration of entospletinib 
monotherap y in 186 subjects with hematologic malignancies are fatigue (53.2%), 
nausea (45.2%), diarrhea (38.7%), decreased appetite (24.7%), constipation (23.7%), 
cough (21.0%), and headache (21.0%) as of 21 Nov ember 2014. 
1.3. Rationale for the Current Study
Hepatic disease may  alter absorption, disposition, and elimination of drugs resulting in 
pharmacokinetic and subsequently  pharmacody namic changes. Available data indicate a hepatic 
role in the disposition of ENT O. Hence, the objective of this study  is to investigate potential 
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 17 28 July 2015alterations in the pharmacokinetics, pharmacod ynamics, and safety of ENTO (and/or its 
metabolites, if applicable) in the context of hepatic insufficiency . The data from this study  will 
direc tly inform dosing recommendations for patients who have liver dy sfunction. 
This study  will be conducted in an adaptive manner. The initial subjects to be enrolled will have 
moderate (Child -Pugh Classification B {3090} ) hepatic functional impairment; data from these 
subjects will be compared to matched subjects with normal hepatic function. Based upon 
adequate safet y and assessment of the pharmacokinetics in these subjects with mode rate hepatic 
impairment (CPT Class B), the stud y will subsequently  evaluate subjects with mild 
(CPT Class A) and/or severe (CPT Class C) hepatic impairment. The planned, staged approach 
of this study  design is consistent with recommendations included in th e FDA Guidance for 
Industry  entitled “Pharmacokinetics in Patients with I mpaired Hepatic Function: Study  Design, 
Data Anal ysis, and Impact on Dosing and Labeling” { 7197} . Such a design enhances subject 
safet y by minimizing the potential for exposing subjects to supratherapeutic exposures of ENTO 
and/or its metabolites (if applicable). Specificall y, the study  will first gen erate pharmacokinetic 
and safet y data in the setting of moderate hepatic impairment where adequate numbers of 
subjects with stable hepatic dy sfunction are available and are suitable for evaluation in a Phase 1 
study . Results obtained from these subjects with moderate impairment are also likely  to yield 
determinative data that indicate either, a) the lack of an effect of moderate hepatic impairment, 
thus obviating the need for evaluation in subjects with mild disease or, alternatively , 
b)thepotential for l arge changes in the exposure of ENTO in the setting of end- organ 
dysfunction that may  provide evidence for a need for caution with respect to an evaluation in the 
setting of severe hepatic dy sfunction.
The trial will enroll subjects with chronicall y impaired hepatic function and healthy  controls, 
matched for bod y mass index, age, and sex. This study  will proceed in a staggered fashion. 
Dosing of subjects with mild and/or severe impairment will occur onl y after the review of safet y 
and pharmacokinetics from subjects with moderate hepatic impairment.
1.3.1. Rationale for the Dose Selection
A therapeutic dose of ENTO 400 mg twice daily is being evaluated in the Phase 2 program in 
subjects with CLL (Study 339 -0102). 
Safety  results from clinical studies to date in dicate that 
ENTO is well tolerated when administered to healthy  subjects at 400 mg BID. In this study , a 
lower dose of ENTO (100 mg) compared to therapeutic dose will be used to evaluate the effect of 
hepatic insufficiency on the PK, PD and safety  of ENTO (and/or its metabolites, if applicable) to 
allow for a potential increase in ENTO exposures due to impaired hepatic metabolism.
ENTO exhibited non -linear PK (i.e. time anddose dependenc y in pharmacokinetic parameters ) in 
Phase 1 studies. Per the FDA’s recommendation {7197 }, a multiple dose hepatic impairment study is 
desirable when the drug or an active metabolite is know n to exhibit nonlinear or time dependent PK. 
Therefore, the current study involves administration of ENTO 100 mg BID for 5 days.
1.4. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regu latory  requirements.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 18 28 July 20152. OBJECTIVES
The primary  objective of this study  isas follows:
To evaluate the pharmacokinetics of Entospletinib (ENTO) and/or its metabolites
(ifapplicable) in subjects with impaired hepatic function relative to matched, healthy  
controls
The secondary  objective of this study  is as follows:
To evaluate the safet y and tolerability  of administration of ENTO in subjects with normal 
and impaired hepatic function
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 19 28 July 20153. STUDY DESIGN
3.1. Study Design
This protocol describes an open- label, parallel -group, adaptive, multiple -dose, Phase 1study  
evaluating the pharmacokinetics of ENTO and/orits metabolites (if applicable) , in subjects with 
impaired hepatic function relative to ma tched, healthy  controls.  
This study  will enroll a minimum of 20 and a maximum of 60 subjects using an adaptive study  
design that includes up to 3 enrolled cohorts of subjects with hepatic impairment as well as 
matched healthy  controls. Eligible subjects 
will be male and nonpregnant, nonlactating female 
subjects, aged ≥ 18 years, 18 BMI 40, with either impaired hepatic function of CPT 
classification A, B, or C or with normal hepatic function. Each subject in the control group will 
be matched to a subje ct with impaired hepatic function by age (± 10years), gender, and bod y 
mass index (± 20%).
When feasible, dosing in a matched control subject with normal hepatic function will occur after 
the subject with impaired hepatic function has completed the PK assessments, except if data exist 
from a subject with normal hepatic function in a previous cohort, this will be used instead of 
enrolling an additional normal health y control subj ect,as permitted in adaptive Cohorts 2 and 3.
Based on safet y and/or PK result s from subjects with moderate hepatic impairment (Cohort 1), 
subjects with severe hepatic impairment (Cohort 2) and/or mild hepatic impairment (Cohort 3) 
will be enrolled as follows:
Cohort 1 ( CPT Class B, Moderate Hepatic Impairment)
20 subjects total:
10 with moderate impairment, 10 matched healthy controls, for 8 evaluable per group
Adaptive Cohort 2 ( CPT Class C, Severe Hepatic Impairment)
Up to 20 subjects: 
10 with severe impairment, up to 10 matched healthy  controls if none of the healthy  subjects
from a previous cohort is an appropriate match for a severe impairment subject, for 
8evaluable per group. 
Adaptive Cohort 3 (CPT Class A, Mild Hepatic Impairment)
Up to 20 subjects: 
10subject s with mild impairment, up to 10 matched health y control su bjects if none of the 
healthy  subjects from a previous cohort is an appropriate match for a mild impairment 
subjec t, for 8 evaluable per group 
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 20 28 July 2015The 90% CIs will be examined to determine if a meaningful change ( ≥ 2-fold mean difference 
from matched controls ) in the exposures of ENTO and/or metabolite (if applicable) exposure is 
identified . Subjects in adaptive Cohort 2 (Severe Hepatic Impairment) and/or adaptive Cohort 3 
(Mild Hepatic Impairment) will be enrolled as determined b y safety (treatment -emergent AEs, 
treatment -emergent laboratory  abnormalities, vital signs, safety  ECGs) and/or PK data from 
Cohort 1 (Moderate Hepatic I mpairment). Specifically , Cohort 2 will be initiated if supported by  
safet y (treatment -emergent AEs, treatment- emergent laboratory  abnormalities, vital signs, safet y 
ECGs) and PK data. Cohort 3 will be enrolled if a clinically meaningful change ( ≥ 2-fold mean 
difference from matched healthy  controls) in the exposures of ENTO and/or metabolite 
(ifapplicable) exposure is identified in Co hort 1.
An overview of the stud y design is shown below in Figure 3-
1
Figure3-1. High Level Study Schema

Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 21 28 July 2015The study  schema for all subjects is shown in Figure 3-2
Figure3-2. Study Schema –All Cohorts 
3.2. Study Drug Administration
Following completion of Screening and Day  -1 assessments, eligible subjects will be enrolled in 
1 of 3 cohorts and receive multiple doses of 100 mg twice daily (BID) E NTO (1 00 mg tablet) 
in the fasted state starting on Day  1 for 5 day s.
Please refer to Section 5.3for additional information for study drug dosage and administration.
3.3. Clinic Confinement
Following completion of S creening and Day -1 assessments, eligible subjec
ts will be confined to 
the study  center starting on Day  -1 until completion of assessments on Day 9.  Subjects will be 
required to return for an in -clinic follow -up visit 14(±1) day s after the last dose of study  drug
(ie, Day  19).
3.4. Pharmacokinetic Assessments
Pharmacokinetic assessments will occur on assigned study day s as outlined in Table 6-1and 
Section 6.7.

Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 22 28 July 20153.4.1. Plasma Pharmacokinetic Collection
Plasma concentrations of Entospletinib and/orits major metabolite (if applicable) will be 
determined and PK parameters estimated. PK of other metabolites (if applicable) of 
Entospletinib may be explored.
3.5. Safety Assessments
Safety  assessments will be performed through the study  as outlined in Table 6-1Section 6.9.
3.6. Genetic Testing
A blood sample for genetic sampling will b e taken in the study  as outlined in Table 6-1
Section 6.10.
A separate, mandatory  blood specimen will be collected for the extraction of DNA for 
genot yping to identify  poly morphisms of drug metabolizing enzy mes (such as CYP2C9, 
CYP3A4/5, CYP1A2 and UGT1A1) and transporters (such as OATP 1B1/3, P -gp, BCRP and 
MATE1) to optimize the therapeutic strategy  for ENTO. This sample should be collected on 
Day -1, before administration of the first dose of study  drug, but may  be collected at any  time 
during clinic confinement.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 23 28 July 20154. SUBJECT POPULA TION
4.1. Number of Subjects and Subject Selection
A minimum of 20 and a maximum of 60 unique subjects will be enrolled in the study , with an 
approximate even distribution of male and nonpregnant, nonlactating female subjects 18years of 
ageor older, with vary ing degrees of hepatic impairment and matched healthy  controls will be 
enrolled. Replacement subjects may  be enrolled if f ewer than 16 evaluable subjects (8 pergroup) 
complete the study  in any  cohort. Replacement subjects will not be enrolled for subjects who 
discontinue the study  due to treatment- related toxicity .
All subjects will be categorized by the Child -Pugh -Turcotte (CPT) classification sy stem 
(Appendix 5) for hepatic impairment as recommended by the United States Food and Drug 
Administration (FDA) and internationa l guidance documents. Within the CPT sy stem, subjects 
will be assigned to Class A, B, or C (CPT Class A, B, or C) based on a cumulative score 
evaluating the presence and severit y of h yperbilirubinemia, hypoalbuminemia, prolongation of 
internationalized nor malized ratio (INR) for coagulation time, ascites, and hepatic 
encephalopath y. Designations of hepatic impairment will be assigned as follows:
Class A (mild): CPT score 5-6
Class B (moderate): CPT score 7 -
9
Class C (severe): CPT score 10 -15
Based on CPT classification, subjects with hepatic impairment and healthy  matched controls will 
be enrolled as described in Section 6.1. The control group will consist of matched healthy  
subjects with normal hepatic function. Each subject in the control gr oup will be matched to a 
subject with impaired hepatic function by  age (± 10 y ears), gender, and body  mass index (± 20%).
4.2. Inclusion Criteria
4.2.1. All Subjects (Healthy Control Subjects and Subjects with Hepatic 
Impairment)
All
subjects must meet allof the following inclusion criteria to be eligible for participation in 
this study .
1)Have the ability  to understand and sign a written informed consent form (ICF), which must 
be obtained prior to initiation of study  procedures
2) Must be ≥ 18 years of age at Screening
3)Have a calculated bod y mass index (BMI) from 18 to40 
kg/m2, inclusive, at study  Screening.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 24 28 July 20154)Have a creatinine clearance ( CrCl) 50mL/min (using the Cockcroft -Gault method {2202} ) 
based on serum creatinine and actual bod y weight as measured at Screening ie.,
Male: (140 –age in years) (wt in kg) CrCl (mL/min)
72(serum creatinine in mg/dL)
Female: (140 –age in years) (wt in kg) 0.85  CrCl (mL/min)
72(serum creatinine in mg/dL)
5)Females of childbearing potential (as defined in Appendix 3) must have a negative serum 
pregnancy  test at Screening and clinic admission.
6)Male subjects and female subjects of childbearing potential who engage in heterosexual 
intercourse must agree to use protocol specified method(s) of contraception as described in 
Appendix 3.
7)Male subjects must refrain from sperm donation from clinic admission, throughout the study  
period, and continuing for at least 90 days following the last dose of 
study  drug.
8)Subjects must refrain from blood donation from cli nic admission, throughout the study  
period, and continuing for at least 30 days following the last dose of study  drug.
9)Have either a normal 12 -lead electrocardiogram (ECG) or one with abnormalit ies that are 
considered clinically  insignificant by  the investigator .
10)Must be willing and able to comply  with all study  requirements.
4.2.2. Subjects with Impaired Hepatic Function
S
ubjects with mild, moderate, or severe hepatic impairment must also meet the foll owing 
additional inclusion criteria to be eligible for pa rticipation in this study :
1)Aside from hepatic insufficiency , the subject must, in the opinion of the I nvestigator, be 
sufficiently  healthy  for study  participation based upon medical history , physical examination, 
vital signs, and screening laboratory  evaluations.
2)Must have diagnosis of chronic (> 6 months), stable hepatic impairment with no clinically  
significant changes within 3 months ( 90 day s)prior to study  drug administration (Day  1).
3) Must meet a ll of the following laboratory  parameters at Screening:
ALT value 10  ULN
AST value  10 ULN
Absolute neutrophil count 1,000/mm3
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 25 28 July 2015Platelets 25,000/mm3
Hemoglobin  8 g/dL
α-fetoprotein  50 ng/mL
4)Subjects with severe hepatic impairment must have a score on the Child- Pugh -Turcotte scale 
of 10 -15 at Screening. If a subject’s score changes during the course of the study , the score at 
Screening will be used for classification.
5)Subjects with moderate hepatic impairment must have a score on the Ch ild-Pugh -Turcotte 
scale of 7-9 at Screening. If a subject’s score changes during the course of the study , the 
score at Screening will be used for classification.
6)Subjects with mild hepatic impairment must have a score on the Ch ild-Pugh -Turcotte scale 
of 5-6at Scr eening. If a subject’s score changes during the course of the study , the score at 
Screening will be used for classification.
4.2.3. Healthy Matched Controlled Subjects
Health y matched control s ubjects must also meet the following additional inclusion criteria to be 
eligible for pa rticipation in this study :
1)Must, in the opinion of the Investigator, be in good health based upon medical history , 
physical examination, vital signs, and screening laboratory evaluations.
2)Must meet all of the following laboratory  paramete rs at Screening:
INR 1 ULN
Albumin 1 LLN
Total bilirubin < 1  ULN
AST value  1 ULN
ALT value 1 ULN 
Alkaline phosphatase 1 ULN
α-fetoprotein  1ULN
Negative Hepatitis B surface antigen (HBsAg)
Negative Hepatitis B core (HBc) antibody  
Negative HCV antibody
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 26 28 July 2015Screening laboratory  evaluations (hematology , fasting lipids, chemistry , and urinaly sis) must 
be within the normal range  unless the results have been determined b y the investigator to 
have no clinical significance.
Have taken an y prescription medications or over -the-counter medications, including herbal 
products, within 28 days prior to start of study  drug dosing, with the exception of vitamins 
and/or acetaminophen and/or ibuprofen.
4.3. Exclusion Criteria
4.3.1. All Subjects 
Any subjects who meet any of the following exclusion criteria are not to be enrolled in this 
study .
1)Pregnant or lactating subjects
2)Have received an y investigational compound within 30 days prior to study  dosing
3)Concurrent participation in another therapeutic clinical trial
4)Current alcohol or substance abuse judged b y the investigator to potentiall y interfere with 
subject compliance or subject safet y
5)Positive test for drugs of abuse, including alcohol at Screening or on Day  -1/check- in
(Positive THC screen a llowed for subjects in states that have legalized THC containing 
substances)
6)A positive test result for human immunodeficiency  virus (HIV -1/HIV -2) antibody , 
hepatiti sB (HBV) surface antigen or current HCV infection (excl ude all subjects who test 
positive (reactive) for HCV antibody with repeat test HCV RNA detected )
7)Have poor venous access that limits phlebotomy
8)History  of having donated blood within 56 day s prior to check in (Day -1).
9)History  of having donated plasma with
in 7 day s prior to check in (Day  -1).
10)History  of prior allogeneic bone marrow progenitor cell or solid organ transplantation.
11)Currently  registered on an organ transplantation list.
12)History  of bleeding from esophageal varices within 90 day s prior to check in (Day -1).
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 27 28 July 201513)Have been treated with sy stemic steroids, immunosuppressant therapies, or chemotherapeutic 
agents within 3 months prior to Screening or expected to receive these agents during the 
study  (eg., corticosteroids, immunoglobulins, and other immune -or cy tokine -based 
therapies)
14) Significant serious skin disease, such as but not limited to rash, food allergy , eczema, 
psoriasis, or u rticaria
15)Significant drug sensitivity  or drug allergy  (such as anaphy laxis or hepatoto xicity )
16)Known hy persensitivity  to the study  drugs ,their metabolites (if applicable), or to formulation 
excipients (see Section 5.2.1)
17)Significant cardiac disease (including history  of my ocardial infarction based on ECG and/or 
clinical history , any  history  of ventricular tachy cardia, congesti ve heart failure, or dilated 
cardiom yopath y with left ventricular ejection fraction <40%), a family history of  Long QT 
Syndrome, or unexplained death in an otherwise healthy  individual between the ages of 1 and 
30years.
18)Presence or history  of cardiovascular disease, cardiomy opath y, and/or clinically  significant 
cardiac conduction abnormalities. 
19)Syncope, palpitations, or unexplained dizziness
20)Implanted defibrillator or pacemaker.
21) Severe peptic ulcer disease, gastroesophageal reflux disease, or other gastr ic acid 
hypersecretory  conditions requiring prolonged (>6 months) medical treatment.
22)Medical or 
surgical treatment that permanentl y alters gastric absorption (eg, gastric or 
intestinal surgery ). A history  of cholecy stectom y is not exclusionary.
23)Subjects with use of strong CYP3A4 inhibitors/CYP3A4 inducers, and strong CYP2C9 
inhibitors/ inducers within 2 weeks prior to stud y drug administration will be excluded
24)Are unable to comply  with study  requirements or are otherwise believed, b y the study  
investigat or, to be inappropriate for study  participation for an y reason.
25) Recent significant changes in the use of nicotine or nicotine containing products 
(ie,initiation, substantial increase or decrease or cessation of use) in the 90 day s prior to
study  drug dos ing, or anticipated significant changes in the use of nicotine or nicotine
containing products during the course of the study through the follow -up visit.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 28 28 July 20154.3.2. Subjects with Impaired Hepatic Function
Subjects with mild, moderate, or severe hepatic impairment meet inganyof the following 
additional exclusion criteria are n ot to be enrolled in this study :
1)Aside from hepatic insufficiency , serious or active medical or ps ychiatric illness that, in the 
opinion of the I nvestigator, would interfere with subject treat ment, assessment, or 
compliance with the protocol. This would include renal, cardiac, hematological, unstable 
hepatic, pulmonary  (including chronic asthma), endocrine (eg, diabetes), central nervous, 
gastrointestinal (including an ulcer), vascular, metabol ic (thy roid disorders, adrenal disease), 
immunodeficiency  disorders, active infection, or malignancy  that are clinically  significant or 
requiring treatment.
2) Requires paracentesis > 1 time per month.
3)Subjects with hepatic impairment with co -morbid diseases requiring medication(s) must be 
taking the medication(s) without a clinically  significant change in dose of con -meds for co-
morbid diseases for > 3 months prior to screening.
All concomitant medications including over -the-counter and herbal products must b e 
approved by the Investigator and Medical Monitor prior to study enrollment and study 
drug administration.
4.3.3. Healthy Matched Controlled Subjects
Health y matched controlled subjects meet inganyof the following additional exclusion criteria 
are n ot to be enr olled in this study :
1)Serious or active medical or psy chiatric illness that, in the opinion of the I nvestigator, would 
interfere with subject treatment, assessment, or compliance with the protocol. This would 
include renal, cardiac, hematological, hepatic, pulmonary  (including chronic asthma), 
endocrine (eg, diabetes), central nervous, gastrointestinal (including an ulcer), vascular, 
metabolic (thy roid disorders, adrenal disease), immunodeficiency  disorders, active infection, 
or malignancy  that are clinicall y significant or requiring treatment.
2)History  of liver disease.
3)Have taken an y prescription medications or over -the-counter medications, including herbal 
products, within 28 days prior to start of study  drug dosing, with the exception of vitamins 
and/or acetaminophen and/or ibuprofen.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 29 28 July 20155. STUDY DRUGS
5.1. Randomization and Blinding
This is an open -label, non -randomized study .
It is the responsibility  of the I nvestigator to ensure that the subject is eligible for the study  prior 
to enrollment. Subjects will be assigned a Screening number at the time of consent.
A minimum of 20 and a maximum of 60 male and non -pregnant, non -lactating female subjects 
with either impaired hepatic function of CPT classification A, B, or C or with normal hepatic 
function will be enrolled to 1 of the 3 cohorts as described in Section 6.1.  
Study  drug will be dispensed by  the study  pharmacist in an open -label fashion to the subjects.
All Screening and check -in(Day -1) tests and procedures must be completed prior to the 
administration of the first dose of study  drug on Day  1. Once a subject number has been assigned 
to a subject, it will not be reassigned to another subject. If necess ary, replacement subjects may  
be enrolled after discussion and approval from Sponsor. A new unique subject number will be 
assigned to the replacement subject. 
A subject number schema will be provided to the study  center b y the Sponsor. Once eligibility  is
confirmed in consultation with the Sponsor, a subject number will be assigned by  the Sponsor.
5.2. Description and Handling of Entospletinib
5.2.1. Formulation
Study  drug entospletinib (ENTO, GS
-9973) is available as 100 mg strength tablets. The tablets 
contain ENTO spray -dried dispersion (SDD) and commonly  used excipients including mannitol, 
poloxamer 188, crospovidone, silicon dioxide, microcry stalline cellulose, magnesium stearate, 
polyethylene gly col, polyviny l alcohol, talc, titanium dioxide, and FD&C blue # 2 aluminum 
lake. ENTO SDD consists of ENTO, methanesulfonic acid, and hy promellose. The 100 mg 
ENTO tablets are blue, ca psule -shaped, plain- faced, film -coated blue tablets.
5.2.2. Packaging and Labeling
ENTO 100 mg tablets are packaged in white, high density  poly ethylene (HDPE) bottles. Each 
bottle contains 60 tablets, silica gel desiccant and poly ester packing material. Each bottle is 
enclosed with a white, continuous thread, child- resistant poly propy lene screw cap with an 
induction- sealed and aluminum -faced line r. 
Study  drug(s) to be distributed to centers in the US and other participating countries shall be 
labeled to meet applicable requirements of the United States Food and Drug Administration 
(FDA), EU Guideline to Good Manufacturing Practice -Annex 13 (I nvestigational Medicinal 
Products), and/or other local regulations.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 30 28 July 20155.2.3. Storage and Handling
ENTO should be stored at a controlled room temperature of 25°C (77°F); excursions are 
permitted from 15°C to 30°C (59°F to 86°F). Storage conditions are specified on the label.  Until 
dispensed to the subjects, all bottles of study  drugs should be stored in a securely  locked area, 
accessible only  to authorized site personnel.
To ensure the stability and proper identification, study drugs should not be stored in a container 
other than the container in which they  were supplied. Consideration should be given to handling, 
preparation, and disposal through measures that minimize drug contact with the body . 
Appropriate precautions should be followed to avoid direct ey e contact o r exposure through 
inhalation when handling.
5.3. Dosage and Administration of Study Drug
Following completion of Screening and Day  -1 assessments, eligible subjects will be enrolled in 
1 of 3 cohorts and receive multiple doses of 100 mg twice daily (BID) ENTO (1 x 00 mg tablet) 
starting on Day  1 in the fasted state .
When feasible, dosing in a control subject with normal hepatic function will occur after the 
matched subject with impaired hepatic function has completed the PK assessments, except for 
control subjects that were alread y matched to a subject with impaired hepatic function in a 
previous cohort, as permitted in adaptive Cohorts 2 and 3.
Subjects in adaptive Cohort 2 (Severe Hepatic Impairment) and/or adaptive Cohort 3 
(Mild Hepatic Impairment) will be enrolled as determined b y safety and/or PK data from 
Cohort 1 (Moderate Hepatic I mpairment). Specifically , Cohort 2 will be initiated if supported by  
safet y and PK findings from subjects in Cohort 1. Cohort 3 will be enrolled if a clinicall y 
meaningful change ( ≥ 2-fold mean difference from matched healthy  controls) in the exposures of 
ENTO and/or metabolite (if applicable) exposure is identified in Cohort 1.
5.4. Fasting and Meals
All study  treatments will be administered at approximately  the same time each day with 240 mL 
of water following an overnight fast (no food or drinks except water, for at least 8 hours).
When ENTO is administered twice a day , the evening dose of ENTO will be administered 
approximately  12 hours after the AM dose. Subjects should continu e fasting for 2 hours post AM 
dose and 2 hours before and 2 hours after the PM dose. Only  the AM dose of ENTO will be 
given on Day  5.
On the day s of intensive pharmacokinetic sampling, study  treatments will be administered in the 
morning following an overn ight fast (no food or drinks except water, for at least 8 hours). 
Subjects will continue to fast until after collection of the 4
-hour pharmacokinetic samples, 
relative to study  drug dosing. Additionally , subjects will be restricted from water consumption
1 hour before until 2 hours after dosing, except for the 240 mL  given with the study  treatment.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 31 28 July 2015All meals and/or snacks given to subjects during their stay  in the clinical study  facility  will be 
standardized for all subjects and should be similar in calorie and fat content and taken at 
approximately  the same time each day .All meals provided must be approved by  the Sponsor.
Components of meals (eg, margarine, jelly , bread) should be given to subjects in individual 
portions (eg, 1 tablespoon) per the approve d meal schedule. The provision of meal components 
in bulk (eg, a jar of jelly  for subjects to share) should not be practiced. All meals should be given 
at approximately  the same time each day  (eg, 07:30, 12:00, and 18:00).
5.5. Dispensing , Accountability, and Disposal or Return ofStudy Drug
The Investigator (or designee, eg, study  center pharmacist) will acknowledge receipt of the study  
drug (after reviewing the shipment’s content and condition) from Gilead (or designee). The 
Investigator will maintain an accu rate inventory  of all study  drug(s). Each dose of the study  
drug(s) administered at the study  center will be administered by  qualified study  center staff . The 
dose of study  drug(s) administered to subjects in the clinic under the supervision of staff will be 
accuratel y recorded on the Study  Drug Accountability  Form provided by Gilead (or on 
equivalent documentation maintained by  the study  center), which indicates the date and quantit y 
of each dosage formulation dispensed to individual subjects.
Gilead recom mends that used and unused study drug supplies, including empty  containers, be 
returned to the shipping facility  from which it came or Gilead Sciences for destruction following 
drug accountability  and drug inventory  reconciliation.
If returning drug suppl ies to the shipping facility  from which it came or to Gilead Sciences is not 
possible , the monitor will evaluate the site’s SOP for study  drug disposal/destruction in order to 
ensure that it complies with Gilead ’srequirements. At the end of the stud y, fol lowing final drug 
inventory  reconciliation by  the monitor, the study site will dispose of and/or destroy  all unused 
study  drug supplies, including empt y containers, according to these procedures. 
5.6. Concomitant Medications and Other Protocol Restrictions
5.6.1. Concomitant Medications 
The following medications are excluded while subjects are participating in the study :
For subjects with normal hepatic function:
Any prescription medications and over -the-counter medications including herbal products 
and antacids with the exception of vitamins, and/or acetaminophen and/or ibuprofen. 
However, the short term use of topical h ydrocortisone cream or A D ointment to treat minor 
skin irritation due to ECG leads will be allowed. If a subject requires use of a disallowed 
medica tion, a request for such use must be reviewed by  the Sponsor and if approved, subjects 
may continue to participate in the study .
For all subjects:
Any and all illegal or illicit drug use , including use of prescription drugs outside the care of 
the prescribing phy sician.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 32 28 July 2015Subjects with hepatic impairment:
Subjects with hepatic impairment with co -morbid diseases requiring medication(s) must be 
taking the medication(s) without a clinically  significant change in dose for > 3 months prior 
to screening. 
All concomitant medications must be approved by the medical monitor (or the clinical 
pharmacologist )prior to enrollment.
5.6.2. Other Protocol Restrictions
Subjects will be required to refrain from the consumption of food and beverages containing 
alcohol products 72 hours prior to the first dose of study  drug and during the course of the 
study  through the follow- up visit.
Subjects will be required to refrain from the use of nicotine or nicotine -containing products 
90 day s prior to first dose of study  drug , and during the course of the study  through the 
follow -up visit. 
Subjects will be required torefrain from consumption of grapefruit juice, grapefruits, and 
Seville orange juice 72 hours prior to the first dose of study  drug and during the course of the 
study  throug h the follow- up visit.
While confined at the study  center, tea, coffee, chocolate, and other foods and beverages 
containing caffeine and other methy l xanthines will be prohibited on each dosing day . Atall 
other times, caffeine -containing beverages and foo dstuffs may be served or withheld in 
accordance with normal study  center practice. Caffeine -containing beverages and foodstuffs 
will not be restricted while subjects are outside of the clinic.
Subjects will be encouraged to avoid strenuous or prolonged exercise, as well as saunas, 
steambaths, and sunbathing or oth er prolonged UV exposure, eg, in a tanning salon, from the 
Screening evaluation until completion of the follow-
up visit, as these activities are known to 
affect certain clinical laboratory  test par ameters, (eg, creatine kinase (CPK)) and will provide 
false indicators of a potentially  treatment -related toxicity . 
Upon every admission to the clinic, each subject will be questioned as to their compliance with 
the above protocol restrictions. If a subje ct is unable to comply  with an y of the restrictions 
described above, the subject’s continued participation in the study  will be reevaluated by  the 
Investigator in consultation with the Sponsor.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 33 28 July 20156. STUDY PROCEDURES
The study  procedures to be conducted for each subject enrolled in the study  are detailed below .
Any deviation from protocol procedures should be noted in the subject’s clinical chart and 
appropriate CRFs / eCRFs . In addition, the Sponsor should be promptly  notified of any  protocol 
deviations. 
The study  center will not initiate dosing until:
The Institutional Review Board (IRB)/Ethics Committee ( EC)/other applicable regulatory  
agencies have reviewed and approved the study  and the informed consent document;
All requested regulatory  documents have been submitted to and approved by  Gilead ;
A Master Services Agreement and/or Study Agreement is executed;
The study  initiation meeting has been conducted by  Gilead (or designee).
The initiation meeting will include but is not limited to a review of the protocol, the IB, study  
drugs, and Investigator responsibilities.
Documentation of the personally  signed and dated informed consent of each subject, using the 
study -specific ,IRB/EC -approved Informed Consent Forms (ICF) , is required before 
initiating 
the screening process. 
6.1. Subject Enrollment and Treatment Assignment
It is the responsibility  of the I nvestigator to ensure that subjects are eligible to participate in the 
study  prior to enrollment and continue to remain eligible throughout the study .
Once informed consent has been obtained, all screening and admission 
tests and procedures have 
been assessed, and stud y eligibility  has been confirmed, subjects will be enrolled to receive study  
drug on Day  1.
Subjects will receive the study  treatme nts as described in Section 5.3.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 34 28 July 2015Table6-1. Schedule of Assessments –All Cohorts
Study Procedure ScreenaDay -1Days 1 
and 5Days 2
and 4 Day 3Days 6,  and 
8 Day 7 Day 9bDay 19(±1) 
FUcETd
Written Informed 
ConsentX
Medical History X
Com plete Physical 
ExamX X X
Symptom -Driven 
Physical Examinatione X X X X
Height X
Weight X X
Vital SignsfX X X X X X X
HIV-1/HIV -2, HBV, 
and HCV SerologyX
Hem atologygX X X X X X
Serum ChemistryhX X X X X X
Genotype Testing for 
Enzymes and 
TransportersXp
Urinalysis X X X X X X
Serum Pregnancy TestiX X XnX X X
FSH testingiX
Urine and Alcohol 
Drug Screen X X XoX X X
12-Lead ECG X X X X X X X
Subject EnrollmentjX
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 35 28 July 2015Study Procedure ScreenaDay -1Days 1 
and 5Days 2
and 4 Day 3Days 6,  and 
8 Day 7 Day 9bDay 19(±1) 
FUcETd
Study Drug 
AdministrationX X X
Intensive Plasma PKkX X X X
Trough PKlXlX
Revie w Study 
Restrictions
Clinic Confinement X X X X X X X
Revie w AEs & 
Concomitant 
MedicationsmX X X X X X X X X X
a Prospective subjects should be screened no more than 28 days prior to administration of the first dose of study drugs.
b Subjects will be discharged from the clinic on Day9,following all morning assessments.
c 14(±1) days after the last administration of study drug, all subjects will return to the clinic for a follow -up visit.
d Assessments will be p erformed within 72 hours of early termination from the study.
e Symptom -driven PE’s will be performed on Days -1, 3, 7, 9,during confinement as needed, and the follow -up visit.
f Vital signs include blood pressure, pulse rate, respiration rate, and body temperature .
g Hematology: INR, CBC with differential and platelet, neutrophil, and hemoglobin count .
h Fasting serum chemistry: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and indirect bilirubin, total protein , albumin , α-fetoprotein, LDH, CPK, bicarbonate, 
BUN, calcium, chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, total cholesterol, HDL, LDL , and triglycerides , and amylase (reflex lipase 
testing is performed in subjects w ith total amylase > 1.5 x ULN).
i Females of child -bearing potential only.
jOnDay -1, subjects w ill be enrolled .
k
Intensive PK sampling will occur relative to the morning dosing of ENTO at the following time points:
Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (pre-PM dose) hours postdose
Day 5: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 84, and 96 hours postdose
l Trough PK sample is taken pre -morning dose on Days 2 and 4 at approximately the same time each day. An additiona l trough PK sample is taken at the Follow Up visit.
m From the time of obtaining informed consent through the first administration of study drug , record all SAEs, as well as any non-serious adverse events related to 
protocol-mandated procedures on the AE eCR F. All other untoward medical occurrences observed during the screening period, including exacerbation or changes in medical 
history are to be captured on the medical history CRF.  See Section 7Adverse Events and Toxicity Management for additional details .
n Day 4 only
o Day 5 only
p Day -1, before administration of the first dose of study drug, or at any time during clinic confinement .
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 36 28 July 20156.2. Pretreatment Assessments
6.2.1. Screening Visit
Prospective subjects should be screened no more than 28 days prior to administration of the first 
dose of study  drug . If the subject does not begin the treatment phase within this 28 -day window, 
all scr eening evaluation procedures must be repeated. Screening labs may  be repeated once 
within 28 day s prior to administration of study  drug to rule out laboratory  error.
Subjects should fast (no food or drink, except water ), starting from midnight (00:00) or e arlier, as 
appropriate, on the evening prior to the Screening visit to ensure an approximate 8-hour fast prior 
to the fasted blood sample collection the next morning.
Written informed consent must be obtained from each subject before initiation of anyscreening 
procedure. After a subject has provided informed consent, the I nvestigator and other study  
personnel will determine if the subject is eligible for participation in the study. This assessment 
will include a review of the inclusion/exclusion crite ria and completion of all screening 
procedures as outlined in Table 6-1and described in the following text. 
Eligible subjects meeting all of the incl usion criteria and none of the exclusion criteria will be 
instructed on all protocol requirements ,including the restrictions on concomitant medication 
usage and other substances as well as consumption of food or beverages containing alcohol, 
caffeine, or xanthine. Subjects will be asked to arrive at the study  center on Day -
1foradmission 
assessments.
From the time of obtaining informed consent through the first administration of study  drug, 
record all SAEs, as well as an y AErelated to protocol -mandated procedures on the AEeCRF.  
All other untoward medical occurrences observed during the screening period, including 
exacerbation or changes in medical history  are to be captured on the medical history  eCRF.  
See Section 7 Adverse Events and Toxicity  Managem ent for additional details.
6.2.2. Admission Assessments
6.2.2.1. Admission
Subjects meeting all eligibility  criteria following the screening evaluation will return to the 
clinic 
for admission assessments on Day  -1. The admission evaluations and/or procedures are outlined
inTable 6-1.
Prior to dosing on Day 1, the results of the clinical and laboratory evaluations (as described in 
Table 6-1) m ust be reviewed by  the Investigator to confirm the continued eligibility  of each 
subject to participate in the study . At the time of randomization, s
ubjects will be assigned a 
sequential subject number as described i n Section 5.1.Subjects will remain confined to the study  
clinic for the duration as described in 
Section 6.2.2.2 and Table 6-1.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 37 28 July 20156.2.2.2. Clinic Confinement
Eligible subjects will be confined to the stud y center beginning Day - 1 until the completion of 
assessments on Day 9. Subjects will return for an in-clinic follow- up visit 14 (±1) day s after the
last dose of study  drug (i.e., Day  19).
6.3. Check-InAssessments
Subjects meeting all eligibility  criteria following the screening evaluation will return to the clinic 
for admission assessments. The admission evaluations and/or procedures are outlined in 
Table 6-1. Subjects should be instructed to fast (no food or drink, except water) for 8 hours prior 
to admission on Day -1, to ensure an approximate 8 -hour fast prior to the fasted blood sample 
collection.
Prior to dosing on Day 1, the r esults of the clinical and laboratory  evaluations (as described in
Section 4.1) must be reviewed b y the Investigator to confirm the continued eligibility  of each 
subject to participate in the study . 
The decision to exclude a subject following that review will 
be made by the Investigator, in consultation with the Sponsor.
Upon confir mation of eligibility , subjects will be assigned a sequential subject number as 
described in Section 5.1. Subjects will remain confined to the clinic for the study  as described in 
Section 3.3and Table 6-1.
6.4. Treatment Assessments
Study  procedures and assessments are outlined in Table 6-1.
6.5. Posttreatment Assessments
All subjects will be instructed to return to the clinic within 14 (± 1) day s after the last dose of 
study  drug for follow -up assessments as outlined in Table 6-
1.
6.6. Assessments for Premature Discontinuation from Study
If a subject discontin ues study  treatment dosing (see Section 6.7), for example as a result of an 
AE, every  attempt should be made to keep the subject in the study  and continue to perform the 
required stud y-related follow
-up procedures. If this is not possi ble or acceptable to the subject or 
Investigator, the subject may  be withdrawn from the study . Evaluations indicating abnormal 
results believed to be possibly  or probably  related to study  treatment at the ETvisit should be 
repeated weekly  or as often as deemed appropriate by  the Investigator until the abnormality  
resolves, returns to baseline visit levels, or is otherwise explained.
If the subject discontinues prematurel y from the study, the ET evaluations and/or procedures 
outlined in Table 6-1should be performed within 72 hours of permanently  discontinuing the 
study  drug.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 38 28 July 20156.7. Criteria for Discontinuation of Study Drug 
Study  medication may  be discontinued in the following instances:
Intercurrent illness that would, in the judgment of the Investigator, affect assessments of 
clinical status to a significant degree
Unacceptable toxicity , as defined in the toxicity  management section of the protocol, or
toxicity  that, in the judgment of the I nvestigator, compromises the ability  to continue 
study -specific procedu res or is considered not to be in the s ubject ’s best interest
Subject request to discontinue for an y reason
Subject noncompliance
Pregnancy  during the study (Refer to Appendix 3)
Investigator discretion
Discontinuation of the study  at the request of Gilead ,regulatory  agency ,or an IRB/EC
6.8. Pharmacokinetic 
Assessments
6.8.1. PlasmaPKCollection
Plasma concentrations for ENTO and/or its metabolites (if applicable) will be determined and 
PK parameters evaluated. Protein binding of ENTO and/or its metabolites (if applicable), may  be 
assessed at their T max time point(s) as well as another later time point.
Intensive PK sampling w ill occur relative to the morning dose of ENTO at the following time 
points:
Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 (pre-PM dose) hours postdose   
Day 5: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 84, and 96 hours postdose
Trough Sampling: Day s 2 and 4: 0 (pre -AM dose, at approximately  the same time each day )
An additional PK sample will be collected at the Day 19Follow -Up visit.
6.9. Safety Assessments
Safety  will be evaluated throughout the study . Refer to Table 6-1for a schedule of assessments.
6.9.1. Electrocardiogram Assessment
Subjects should rest quietly  in the supine position for a minimum of 10 minutes prior to each 
scheduled ECG acquisition and should remain in that position until the recording is complete.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 39 28 July 2015There should be no environmental distractions ( eg., TV, radio, conversation, etc.) while the 
subjects are resting prior to and during the recordings. Electrocardiograms will be recorded using 
the site’s standard ECG equipment. All ECGs will be obtained using ins truments that analy ze 
data using the same algorithms and produce the same data for interpretation. Electrode placement 
will be performed according to the method of Wilson, Goldberger, and Einthoven with a check 
to confirm that the aVR lead is not inverted.
The Investigator or other qualified individuals at the study  center will review ECGs to assess for 
changes in ECG intervals and morphology  as compared to pretreatment ECGs. ECG interval 
measurements output b y the machine will be used for bedside safet y mo nitoring.
Collection of additional ECGs for routine safet y monitoring at additional time points or day s is at 
the discretion of the Investigator based on GCP .
6.9.2. Physical Examination
Physical examinations conducted throughout the study  will be a complete phy sical examination 
or a s ymptom -directed phy sical examination ,as outlined in Table 6-1. The complete phy sical 
examination conducted at S creening will also include the following assessments:
Review medical history , including history  of allergies, and history  of prior and current use of 
nicotine or nicotine -containing products, history  of alcohol and illegal drug use; and history  
of prior (within 30 day s,or within 3 months for systemic steroids, immunosuppressant 
therapies, or chemotherapeutic agents ) and current medication use.
6.9.3. Vital Signs
Vital sign measurements include blood pressure, pulse, respirat
ion rate, and temperature and will 
occur throughout the study and will be recorded as outlined in Table 6-1. Vital signs (s ystolic 
blood pressure, diastolic blood pressure, respiration rate, temperature and heart rate) should be 
taken once subjects have been seated or in the supine position for a minimum of approximately  
5 minutes. Subject position for measurement should be kept consistent throughout the stud y.  
Vital signs should be assessed prior to study  drug administration. Refer to Table 6-
1forvital 
signs collection time points.
6.9.4. Body Mass Index
Height and weight will be collected at Screening for calculation of BMI for inclusion criteria.
6.9.5. Clinical Laboratory Tests/Assessments
Blood and urine samples for safety  evaluations will be collected throughout the study  as outlined 
in Table 6-1.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 40 28 July 20156.9.5.1. Blood Sampling
Blood samples will be collected for the following laboratory  anal yses:
Hematology : INR, CBC with differential and platelet, neutr ophil, and hemoglobin count.
Serum chemistry  (fasting): alkaline phosphatase, AST, AL T, GGT , total bilirubin, direct and 
indirect bilirubin, total protein, albumin, α- fetoprotein ,LDH, CPK, bicarbonate, BUN, 
calcium, chloride, creatinine, glucose, phosphor us, magnesium, potassium, sodium, uric acid, 
total cholesterol, HDL, LDL , and trigly cerides, and amy lase (reflex lipase testing is 
performed in subjects with total amy lase > 1.5 x ULN).
Serum pregnancy  test (females of childbearing potential only )
FSH (fem ales onl y)
HIV, HBV, and HCV testing (Screening onl y)
Genoty ping for drug metabolizing enzy mes and transporters (Day  -1 only , or any  day during 
clinic confinement )
6.9.5.2. Urine Samples
Urine samples will be collected for urinal ysis and urine alcohol and drug screening assessments.
6.9.6. Creatinine Clearance
Weight will be collected at Screening and upon admission tocalculate creatinine clearance 
(using the Cockcroft -Gault method) for inclusion criteria.
6.9.7. Adverse Events/Concomitant Medications/Protocol Restrictions
Evaluation for AEs, review of concomitant medications, and review of protocol restrictions will 
occur at the times shown in Table 6-1. See Section 7for more information regarding AEs and 
Sections 4.3and Section 5.6.1 for more information about concomitant medications.
6.10. Genetic Testing
A blood sample for genetic sampling will be taken in the study  as outlined in Table 6-1.
A separate, mandatory  blood specimen will be collected for the extraction of DNA for 
genot yping to identify  poly morphisms of drug metabolizi ng enzy mes (such as CYP2C9, 
CYP3A4/5, CYP1A2 and UGT1A1) and transporters (such as OATP 1B1/3, P -gp, BCRP and 
MATE1) to optimize the therapeutic strategy  for ENTO. This sample should be collected on 
Day -1, before administration of the first dose of study  drug, but may  be collected at any  time 
during clinic confinement.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 41 28 July 20156.11. Sample Storage
 
 
PPD
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 42 28 July 20157. ADVERSE EVENTS AND TOXICITY  MANAGEMENT
7.1. Definition sof Adverse Events , Adverse Reactions, and Serious Adverse 
Events
7.1.1. Adverse Events
An AE is an y untoward medical occurrence in a clinical study subjec t administered a medicinal 
product, which does not necessarily  have a causal relationship with the treatment. An AE can 
therefore be an y unfavorable and/or unintended sign, s ymptom, or disease temporally  associated 
with the use of a medicinal product, whet her or not considered re lated to the medicinal product. 
AEs may  also include pre -or post treatment complications that occur as a result of protocol 
specified procedures, lack of efficacy , overdose ,drug abuse/misuse reports , or occupational 
exposure .Preexisting events that increase in severity  or change in nature during or as a 
consequence of participation in the clinical study  will also be considered AEs.
An AE does not include the following:
Medical or surgical procedures such as surgery , endoscopy ,tooth extraction, and transfusion. 
The condition that ledto the procedure may  be an AEand must be reported.
Preexisting diseases, conditions, or laboratory  abnormalities present or detected before the 
Screening visit that donot worsen
Situations where an untoward medical occurrence has not occurred (eg. ,hospitalization for 
elective surgery , social and/or convenience admissions)
Overdose without clinical sequelae (see Section 7.7.1 .)
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. I t is c onsidered to be pre existing and should be documented on the medical history  CRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an
event that, at any dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the definition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospitalization or prolongation of existing hospitalization
Persistent or significant disability /incapacit y
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 43 28 July 2015A congenital anomal y/birth defect
A medicall y important event or reaction: such events may  not be immediately  
life-threatening or result in death or hospitalization but may  jeopardize the subject or may  
require intervention to prevent one of the other outcomes constituting SAEs. Medical and 
scientific ju dgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of m edically  i
mportant e vents include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization; anddevelopment of drug dependency  or 
drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal 
product will be considered a m edicall y important 
event and subject to expedited reporting 
requirements.
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , and urinaly sis) that 
require medical or surgical intervention or lead to study  drug interruption, modification, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, ECG , x-rays, vital signs) that are associated with 
signs and/or s ymptoms must be recorded as an AE or SAE if they  meet the definition of an AE 
or SAE as described in Sections 7.1.1 and 7.1.2. If the laboratory  abnormality  is part of a 
syndrome, recor d the s yndrome or diagnosis (eg, anemia), not the laboratory  result (ie, decreased 
hemoglobin).
For specific information on handling of clinical laboratory  abnormalities in this study , please 
refer to Section 7.5.
7.2. Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality  and severity , and for final revi ew and confirmation of accuracy  of event information 
and assessments
.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The Investigator or qualified subinvestigator is responsible for assessing t he relationship to study  
drug using clinical judgment a nd the following considerations:
No: Evidence exists that the AEhas an etiology  other than the study  drug. For SAEs, an 
alternative causality  must be provided (eg, pre existing condition, underl ying disease, 
intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused by the study  drug .
It should be emphasized that ineffective treatment should not be considered as causall y related in 
the context of AE reporting. 
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 44 28 July 2015The relationship to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No: Evidence exists that the AE has an etiology  other than the study  procedure.
Yes: The AEoccurred as a result of protocol procedur es,(eg., venipuncture)
7.2.2. Assessment of Severity
AE severit y should be recorded and graded according to the CTCAE Grading Scale for Severity  
of Adverse Events and Laboratory  Abnormalities (Appendix 4).For adverse events associated 
with laboratory  abnormali ties, the event should be graded on the basis of the clinical severity  in 
the context of the underly ing conditions; this may or may  not be in agreement with the grading 
of the laboratory  abnormality .
The distinction between the seriousness and the severity of an adverse event should be noted. 
Severe is a measure of intensity ; thus, a severe reaction is not necessaril y a serious reaction. For 
example, a headache may be severe in intensity
, but would not be classified as serious unless it 
met one of the crite ria for serious events.
7.3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to Gilead 
7.3.1.
Requirements for collection prior to study drug initiation:
After informed consent, but prior to initiation of study  medication, the following t ypes of events 
should be reported on the case report form (CRF/eCRF): all SAEs and AErelated to 
protocol -mandated procedures.
7.3.1.1. Adverse Events
Following initiation of study  medication, collect a ll AEs, regardless of cause or relationship, 
until 30 day safter last administration of study  drug must be reported to the CRF/eCRF database 
as instructed.
All AEs should be followed up until resolution or until the AEis stable, if po ssible. 
Gilead Sciences may  request that certain AEs be followed bey ond the protocol defined follow up 
period.
7.3.1.2. Serious Adverse Events
All SAEs, regardless of cause or relationship, that occur safter the subject first consents to 
participate in the stud y (ie, signing the informed consent) and throughout the duration of the 
study , including the protocol -required post treatment follow -up period, must be reported to the 
CRF/eCRF database and Gilead DSPH as instructed. This also includes any  SAEs resulting from 
protocol -associated procedures performed after informed consent is signed.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 45 28 July 2015Any SAEs and deaths that occur after the post treatment follow -up visit but within 30 days of the 
last dose of study  IMP, regardless of causalit y, should also be reported.
Investigators are not obligated to activel y seek SAEs after the protocol defined follow up period, 
however, if the investigator learns of an y SAEs that occur after stud y participation has concluded 
andthe event is deemed relevant to the use of study  drug , he/she should promptly  document and 
report the event to Gilead DSPH.
All AEs and SAEs will be recorded in the CRF/eCRF database within the timelines outlined 
in the CRF/eCRF completion guideline.
At the time of study  start, SAEs will be reported using a paper serious AEreporting form. 
During the study  conduct, sites may  transition to an electronic SAE (eSAE) sy stem. Gilead 
will notify  sites in writing and provide training and account information prio r to 
implementing an eSAE system.
7.3.1.3. Serious Adverse Event Paper Reporting Process
All SAEs will be r ecord ed on the 
SAE report form a ndsubmitted by  faxing or emailing the 
report form 
within 24 hours of the investigator’s knowledge of the event to the attenti on of 
Gilead DSPH 
or to the designated CRO.
7.3.1.4. Electronic Serious Adverse Event (eSAE) Reporting Process 
Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to Gilead DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.
If for an y reason it is not possible to record the SAE information electronically , ie, the eCRF 
database is not functioning, record the SAE on the paper SAE reporting form and submit 
within 24 hours to: Email:  and Fax: 
As soon as it is possible to do so, any SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.
If an SAE has been reported via a paper form because the eCRF database has been locked, no 
further action is necessary.
For fatal or life -threatening events, copies of hospital case
reports, autops y reports, and other 
documents are alsoto be submitted by e-mail or fax when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the tra ceability  of a document to the s ubject i dentifiers.Gilead DSPH: Fax 
Email: 
PPD
PPD
PPD
PPD
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 46 28 July 2015Additional information may  be requested t o ensure the timely  completion of accurate safet y 
reports.
Any medications necessary  for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s CRF/ eCRF an d the event description section of the SAE 
form.
7.4. Gilead Reporting Requirements
Depending on relevant local legislation or regulations, including the applicable US FDA Code of 
Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant u pdates, and 
other country -specific legislation or regulations, Gilead may  berequired to expedite to 
worldwide regulatory  agencies reports of SAEs , serious adverse drug reactions (SADRs) ,or 
suspected 
unexpected serious adverse reactions (SUSARs). In accordance with the EU Clinical 
Trials Directive (2001/20/EC), Gilead or a specified designee will notify  worldwide regulatory  
agencies and the relevant IECin concerned Member States of applicable SUSARs as outlined in 
current regulations.
Assessment of e xpectedness forSAEs will be determined by  Gilead using reference safety  
information specified in the IBor relevant local label as applicable. 
All investigators will receive a safet y letter notifying them of relevant SUSAR reports associated 
with any  study  drug . The investigator should notify  the IRB or IEC of SUSAR reports as soon as 
is practical, where this is required b y local regulatory agencies
, and in accordance with the local 
institutional policy . 
7.5. Clinical Laboratory Abnormalities and Other Abn ormal Assessments as 
AdverseEvents or Serious Adverse Events
Laboratory  abnormalities are usuall y not recorded as AEs or SAEs. However, laboratory  
abnormalities (eg, clinical chemistry , hematology , and urinal ysis) that require medical or surgical 
intervention or lead to investigational medicinal product interruption or discontinuation must be 
recorded as an AE, as well as an SAE, if applicable. In addition, laboratory  or other abnormal 
assessments (eg, electrocardiogram, X -rays, vital signs) that are assoc iated with signs and/or 
symptoms must be recorded as an AE or SAE if they  meet the definition of an AE or SAE as 
described in Sections 7.1.1 and 7.1.2 respectivel y. If the laboratory  abnormality  is part of a 
syndrome, record the s yndrome or diagnosis (ie, anemia) not the laboratory result (ie, decreased 
hemoglobin).
Severity  should be recorded and graded according to the GSI Grading Scale for Severit yof 
Adverse Events and Laboratory  Abnormalities ( Appendix 4). 
For AEs associated with laboratory  abnormalities, the event should be graded on the basi s of the 
clinical severit y in the context of the underlying conditions; this may or may not be in agreement 
with the grading of the laboratory  abnormality .
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 47 28 July 20157.6. Toxicity Management 
Treatment -emergent toxicities will be noted by the investigator a nd brought to the attention of 
the Gilead Sciences Medical Monitor or designee. Whether or not considered treatment -related, 
all subjects experiencing AEs must be monitored periodicall y until symptoms subside, any 
abnormal laboratory  values have resolved o r returned to baseline levels or they  are considered
irreversible, or until there is a satisfactory explanation for the changes observed.
Clinical events and clinically significant laboratory  abnormalities will be graded according to the 
GSIGrading Scale for Severity  of Adverse Events and Laboratory  Abnormalities (Appendix 4).
Grade 3 and 4 clinicall y significant laboratory  abnormalities should be confirmed by  repeat 
testing as soon as practical to do so, and preferably within 3 calendar day s after recei pt of the 
original test results.
Any questions regarding toxicity  management should be directed to the Gilead Medical 
Monitor.
7.7. Special Situations Reports
7.7.1. Definitions of Special Situations
Special situation reports includ e all reports of medication error, abuse, misuse, overdose, reports 
of AEs associated with product complaints, and pregnancy  reports regardless of an associated 
AE.  
Medication error is an y unintentional error in the prescribing, dispensing ,or administration of a 
medicinal product while in the control of the health care provider , 
subject, or consumer.
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by  a 
subject.
Misuse is defined as an y intentional and inappropriate useof a medicinal p roduct tha t is not in 
accordance with the protocol instructions or the local prescribing information .
An overdose is defined as an accidental or intentional administration of a quantity  of a medicinal 
product given per administration or cumulatively  which is above t he maximum recommended 
dose as per protocol or in the product labelling (as it applies to the daily  dose of the subject in 
question). In cases of a discrepancy  in drug accountability , overdose will be established only  
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy  except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.  
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 48 28 July 20157.7.2. Instructions for Reporting Special Situations
7.7.2.1. Instructions for Reporting Pregnancies
The investigator should report pregnancies in female study  subjects that are identified after 
initiation of study  medication and throughout the study , including the post study  drug follow -up 
period, to Gilead DSPH using the pregnancy  report form within 24 hours of becoming aware of 
the pregnancy . 
Refer to section 7.3and the CRF/eCRF completion guidelines for full instructions on the 
mechanism of pregnancy reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
Any premat ure termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported within 24 hours as an 
SAE. The underl ying medical reason for this procedure should be recorded as the AEterm.
A spontaneous abortion is alway s considered to be an SAE and w ill be reported as described in 
Section 7.3.Furthermore, any  SAE oc curring as an adverse pregnancy  outcome post study  must 
be reported to Gilead DSPH .
The subject should receive appropriate monitoring and care until the conclusion of the 
pregnancy . The outcome should be reported to Gilead DSPH using the pregnancy  outcome report 
form. If the end of the pregnancy  occurs after the study  has been completed, the outcome should 
be reported directl y to Gilead DSPH. Gilead DSPH contact information is as follows: 
Email:  and Fax:  
Pregnancies of female partners of male study  subjects exposed to Gilead or other study  drugs 
must also be reported and relevant information should be submitted to or Gilead DSPH using the 
pregnancy  and pregnancy  outcome forms within 24 hours. Monitoring of the subject should 
continue until the conclusion of the pregnancy . If the end of the pregnancy  occurs after the study  
has been completed, the outcome should be reported directl y to Gilead DSPH, 
faxnumber  or email  
Refer to 
Appendix 3for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements.
7.7.2.2. Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to Gilead DSPH within 24 hours of the investigator becoming aware of the situation. 
These reports must consist of situations that involve study drug and/or Gilead concomitant 
medications, but do not apply
 to non-Gilead concomitant medications. 
PPD
PPD
PPD
PPD
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 49 28 July 2015Special situations involving non-Gilead concomitant medications does not need to be reported on 
the special situations report form; however, for special s ituations that result in AEs due to a 
non-
Gilead concomitant medication, the AE should be reported on the AE form . 
Any inappropriate use of concomitant medications prohibited by  this protocol should not be 
reported as “misuse,” but may  be more appropriate ly documented as a protocol deviation.
Refer to section 7.3and the CRF/eCRF completion guidelines for full instructions on the 
mechanism of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE CRF/eCRF and/or the SAE report form. Details of the sy mptoms 
and signs, clinical management, and outcome will be reported, when available.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 50 28 July 20158. STATISTICAL  CONSIDER ATIONS
8.1. Analysis Objectives and Endpoints
8.1.1. Analysis O bjectives
The primary  anal ysis objective of this study  is to evaluate the PK of ENTO and/or its metabolites
(if applicable) in subjects with impaired hepatic function relative to matched, healthy  controls.
The secondary  analy sis objective of this study  is to evaluate the safet y and tolerability of ENTO
in subjects with normal and impaired hepatic function.
8.1.2. Primary Endpoint
The primary  endpoints are the PK parameters AUC and C maxof ENTO and/or its metabolites
(ifapplicable) .
8.1.3. Secondary Endpoint
The secondary  endpoints are the incidences of adverse events and laboratory  abnormalities.
8.2. Analysis Conventions
8.2.1. Analysis Sets
8.2.1.1. PK Analy sis Set
The PK anal ysis set will include all enrolled/randomized subjects who received at least 1 dose of 
study  drug ( ENTO ) and had at least 1 non -missing PK concentration data reported by  PK lab for 
each respective anal yte. This is the primary  anal ysis set for PK summaries.
8.2.1.2. Safety  Anal ysis Set
The safet y analysis set will include all enrolled subjects who received at least 1 dose of study  
drug. This is the primary  anal ysis set for safet y summaries.
8.2.1.3. All Enrolled Anal ysis Set
The all enrolled anal ysis set will include all subjects who were enrolled into the study . This is the 
primary  anal ysis set for safet y listings.
8.3. Data Handlin g Conventions
For summary  statistics, PK concentration values below the limit of quantitation (BLQ) will be 
treated as zero at predose and one-half of the lower limit of quantitation (LLOQ) for postdose 
timepoints, where LLOQ is corrected for the dilution 
factor (ie, reported dilution/dilution factor). 
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 51 28 July 2015Laboratory  data that are continuous in nature but are less than the lower limit of quantitation or 
above the upper limit of quantitation will be imputed to the value of the lower or upper limit 
minus or plus one significant digit, respectivel y (eg, if the result of a continuous laboratory  test is 
<20, a value of 19 will be assigned; if the result of a continuous laboratory test is < 20.0, a value 
of 19.9 will be assigned).
Missing data can have an impact upo n the interpretation of the trial data. As this study  is of short 
duration, it is anticipated that missing data will be minimal. I n general, values for missing data 
will not be imputed. However, a missing pretreatment laboratory  result would be treated as 
normal (ie., no toxicity grade) for the laboratory  abnormality  summary .
8.4. Demographic Data and Baseline Characteristics
Demographic and baseline measurements will be summarized and descriptive statistics will be 
provided. 
8.5. Safety Analysis
All safet y data col lected on or after the date that study  drug was first administered up to the date 
of last dose of stud y drug plus 30 days will be listed and summarized using safet y analysis set . 
8.5.1. Extent of Exposure
A subject’s extent of exposure to study  drug data will be generated from the study  drug 
administration page in eCRF. Exposure data will be listed.
8.5.2. Adverse Events
Clinical and laboratory  AEs will be coded using the Medical Dictionary  for Regulatory  
Activities (MedDRA). Sy stem Organ Class (SOC), High -Level Group T erm (HLGT), 
High -Level Term (HLT), Preferred Term (PT), and L ower -Level Term (LLT) will be attached to 
the clinical database.
Adverse event data will be listed by  subject. Treatment -emergent AE (TEAE) and Serious TEAE 
will be summarized by  system organ cla ss and preferred term using the current version the 
Medical Dictionary  for Regulatory  Activities (MedDRA). 
8.5.3. Laboratory Evaluations
Selected laboratory  data (clinical chemistry  and hematology ) will be summarized using onl y 
observed data. Absolute values and change from predose at all scheduled time points will be 
summarized. 
Laboratory  abnormalities will be graded using GSI Grading Scale for Severity  of Adverse Events 
and Laboratory  Abnormalities ( Appendix 4) for analysis purposes. 
Incidence of treatment -emergent laboratory  abnormalities, defined as values that increase at least 
one toxicity  grade from predose at any  time postdose up to the completion of study  follow -up, 
will be summarized. If predose data are missing, then any  graded abnormality  (ie, at least a 
Grade 1) will be considered treatment emergent. 
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 52 28 July 2015Laboratory  abnormalities that occur before the first dose of investigational medicinal product or 
after the completion of study  follow -up will be included in a data listing .
8.5.4. Other Safety Evaluations
ECG data willbesummarized over time andpresented inalisting.
Individual data forvital signs measurements willbelisted bysubject andsummarized using 
incide nce(frequencies) ofevents/ abnormalities ordescriptive statistical summaries (eg,n,mean, 
SD,median, andrange), asappropriate.
8.6. Pharmacokinetic Analysis
Plasma concentrations of ENTO and /or its metabolites (if applicable) over sampling time will be 
listed and summarized by  hepatic function group. 
Plasma concentrations of ENTO and /or its metabolites (if applicable) over time will be plotted in 
semi -logarithmic and linear formats as mean SD and as median (Q1, Q3). 
The PK parameters will be listed and summarized for ENTO and/orits metabolites
(ifapplicable) using descriptive statistics ( e.g., sample size, arithmetic mean, geometric mean, 
%CV, SD, median, minimum, and maximum) by  hepatic function group (normal or CPT 
ClassA, B, or C). 
A parametric (normal theory ) ANOVA model appropriate for a parallel design will be fitted to 
the natural logarithmic transformation of PK parameters ( AUC tauand C max) for ENTO and/or its 
metabolites (if applicable) . The 90% CIs will be con structed for the GLSMratios of PK 
parameters for ENTO and/or its metabolites (if applicable) in each hepatic impairment group 
versus the matched control (normal hepatic function) group. The 90% CIs will be examined to 
determine if the GLSM ratio is within limits of 50% to 200% .
ENTO percent protein binding will be summarized by  hepatic function group and data for 
individual subjects will be presented in a listing (if applicable) . 
8.7. Sample Size
A sample size of 8 evaluable subjects per group will provide a ≥ 89% probability  forthe 90% CI 
for the GLSM ratio of pharmacokinetic parameters (AUC or C max) for ENTO in the hepatic 
impairment/dy sfunction group(s) versus the appropriate group of matched controls, to be within 
limits of 50% to 200% . The calculation assumes an expected ratio of geometric means of 1.0 in 
pharmacokinetic parameters and inter -subject standard deviation of 0.455 for the natural 
logarithm -transformed pharmacokinetic parameters for ENTO. The assumption is based on the 
data obtained from a prio r clinical study  of ENTO (Study  GS-US-339- 0111).
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 53 28 July 20159. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Practice
The investigator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended i n Edinburgh, Toky o, Venice, Hong Kong, and 
South Africa), International Conference on Harmonisation (I CH) guidelines, or with the laws and 
regulations of the country  in which the research is conducted, whichever affords the greater 
protection to the study  subject. These standards are consistent with the European Union Clinical 
Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 CFR 312, subpart D, “Responsibilities of Sponsors and Investigators,” 21 CFR, 
part50, "Protection of Human Subjects" , and 21 CFR, part 56, 
"Institutional Review Boards" .
The investigator and all applicable subinvestigators will comply  with 21 CFR, Part 54, 
"Financial Disclosure b y Clinical I nvestigators", providing documentation of their financial 
interest or arrangements with Gilead, or proprietary interests in the study drug under study . This 
documentation must be provided prior to the investigator’s (and an y subinvestigator’s) 
participation in the study. The investigator and subinvestigator agree to notify  Gilead of any  
change in reportable interests during the study  and for 1 year following completion of the study. 
Study  completion is defined as the date when the last subject completes the protocol -defined 
activities.
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (EC) 
Review and Approval
The investigator (or Sponsor as appropriate according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study  used to obtain 
informed consent) to an IRB/EC . The investigator will not begin an y stud y subject activities until 
approval from the IRB/IEC has been documented and provided as a letter to the investigator.
Before implementation, the investigator will submit to and receive documented approval from 
the IRB/EC an y modifications made to the protocol or any accompan ying material to be 
provided to the subject after initial IRB/EC approval, with the exception of those necessary  to 
reduce immediate risk to study  subjec ts.
9.1.3. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  and before undertak ing an y stud y-related procedures. The 
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 54 28 July 2015investigator must use the most current IRB -or EC -approved consent form for documenting 
written informed consent. Each informed consent (or assent as applicable) will be appropriatel y 
signed and dated b y the subject or the subject’s legall y authorized representative and the person 
conducting the consent discussion, and also by  an impartial witness if required by  IRB or EC or 
local requirements. 
9.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity  will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only subject initials, date of birth, another 
unique identifier (as allowed by local law) and an identification code will be recorded on an y 
form or biological sample submitted to the Sponsor, IRB/EC , or laboratory . Laboratory  
specimens must be labeled in such a way  as to protect subject identity  while allowing the results 
to be recorded to the proper subject. Refer to specific laboratory  instructions or in accordance 
with local regulations. NOTE: The investigator must keep a screening log showing codes, names, 
and addresses for all subjects screened and for all subjects enrolled in the trial. Subject data will 
be processed in accordance with all applicable regulations.
The investigator agrees that all information received from Gilead, including but not limited to the 
investigator brochure, this protocol, CRF/eCRF, the study  drug , and any  other study  information, 
remain the sole and exclusive propert y of Gilead during t he conduct of the study  and thereafter. 
This information is not to be disclosed to an y third party (except emplo yees or agents directly  
involved in the conduct of the study  or as required by  law) without prior written consent from 
Gilead. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain.
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the study  
to be fully  documented and the study data to be subsequently  verified. These documents should 
be classified into at least the following two categories: (1)investigator’s study  file, and 
(2)subject clini cal source documents.
The investigator’s stud y file will contain the protocol/amendments, CRF and query  forms, 
IRB/EC and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identification (name, date of birth, gender);
Documentation that subject meets eligibi lity criteria, ie, history , phy sical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);
Documentation of the reason(s) a consented subject is not enrolled
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 55 28 July 2015Participation in study  (including study  number);
Study  discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures were performed;
Results of efficacy  parameters, as required b y the protocol;
Start and end date (including dose regimen) of study  drug , including dates of dispensing and 
return;
Record of all AEs and other safety  parameters (start and end date, and including causality  
and severit y);
Concomitant medication (including start and end date, dose if relevant; dose changes);
Date of stud y completion and reason for early discontinuation, if it occurs.
All clinical study  documents must be retained b y the investigator until at least 2 years or 
according to local laws, whichever is longer, after the last approval of a marketing application in 
an ICH region (ie, United States, Europe, or Japan) and until there are no pending or planned 
marketing applications in an I CH region; or, if no application is filed or if the application is not 
approved for such indication, until 2 years after the investigation is discontinued and regulatory  
authorities have been notified. Investigators may  be required to retain documents longer if 
specified b y regulatory  requirements, by  local regulations, or by  an agreement with Gilead. The 
investigator must notify  Gilead before destro ying any  clinical study  records.
Should the investigator wish to assign the stud y records to another part y or move them to another 
location, Gilead must be notified in advance.
If the investigator cannot provide for this archiving requirement at the study site for an y or all of 
the documents, special arrangements must be made between the investigator and Gilead to store 
these records securel y awa y from the site so that they can be returned sealed to the investigator 
in case of an inspection. When source documents are required for the continued care of the 
subject, appropriate copies should be made for storage away  from the site.
9.1.6. Case Report Forms
For each subject consented, an eCRF will be completed by  an authorized study  staff member 
whose training for this function i s documented according to stud y procedures. eCRF should be 
completed on the day  of the subject visit to enable the sponsor to perform central monitoring of 
safet y data.  The Eligibility  Criteria eCRF should be completed onl y after all data related to 
eligibility  have been received.  Subsequent to data entry , a study  monitor will perform source 
data verification within the EDC system. Original entries as well as any  changes to data fields 
will be stored in the audit trail of the system.  Prior to database lock (or an y interim time points 
as described in the clinical data management plan), the investigator will use his/her log in 
credentials to confirm that the forms have been reviewed, and that the entries accuratel y reflect 
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 56 28 July 2015the information in the source do cuments. The eCRF capture the data required per the protocol 
schedule of events and procedures. System -generated or manual queries will be issued to the 
investigative site staff as data discrepancies are identified by  the monitor or internal Gilead staff , 
who routinely  review the data for completeness, correctness, and consistency . The site 
coordinator is responsible for responding to the queries in a timel y manner, within the system, 
either b y confirming the data as correct or updating the original entr y, and providing the reason 
for the update (e.g. data entry  error). At the conclusion of the trial, Gilead will provide the site 
with a read -only archive copy  of the data entered by  that site. This archive must be stored in 
accordance with the records re tention requirements outlined in Section 9.1.5 .
9.1.7. Study Drug Accountability and Return  
Gilead recommends that used and unused study  drug supplies be returned to the shipping facility  
from which it came for eventual destruction. The study  monitor will provi de instructions for 
return. If return is not possible, the study  monitor will evaluate each stud y center’s study  drug
disposal procedures and provide appropriate instruction for destruction of unused study  drug
supplies. I f the site has an appropriate standard operating procedure (SOP) for drug destruction
as determined by Gilead QA , the site may  destro y used (empt yor partially  empty ) and unused 
study  drug supplies in accordance with th atsite’s approved SOP. A cop y of the site’s approved 
SOP will be obtai ned for central files. 
Ifstudy  drug is destro yed on site, the investigator must maintain accurate records for all study  
drug destroy ed. Records must show the identification and quantity  of each unit destroy ed, the 
method of destruction, and the 
person who disposed of the study  drug . Upon study  completion, 
copies of the study  drug accountability  records must be filed at the site. Another copy  will be 
returned to Gilead .
The study  monitor will review study  drug supplies and associated records at pe riodic intervals.
9.1.8. Inspections
The investigator will make available all source documents and other records for this trial to 
Gilead’s appointed stud y monitors, to IRB/EC ,or to regulatory  authorit y or health authority  
inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
9.2. Sponsor Responsibilities
9.2.1. Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study subjects, may  be 
made only  by Gilead. The investigator must submit all protocol modifications to the IRB/EC in 
accordance with local requirements and receive documented IRB/EC approval before 
modifications can be implemented.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 57 28 July 20159.2.2. Study Report 
A clinical study  report (CSR) will be prepared and provided to the regulatory  agency (ies).Gilead 
will ensure that the report meets the standards set out in th eICH Guideline for Structure and 
Content of Clinical Study Reports (I CHE3). Note that an abbrevia ted report may  be prepared in 
certain cases. 
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may  be asked to provide services performed under this 
protocol, eg ,attendance at I nvestigator's Meetings. If re quired under the applicable statutory  and 
regulatory  requirements, Gilead will capture and disclose to Federal and State agencies any  
expenses paid or reimbursed for such services, including an y clinical trial payments, meal, travel 
expenses or reimburseme nts, consulting fees, and any  other transfer of value.
9.3.2. Access to Information for Monitoring
In accordance with regulations and guidelines, the study  monitor must have direct access to the 
investigator’s source documentation in order to verify  the accuracy  of the data recorded in the 
CRF/eCRF.
The monitor is responsible for routine review of the CRF/eCRF at regular intervals throughout 
the study  to verify  adherence to the protocol and the completeness, consistency , and accuracy  of 
the data being entered on t hem. The monitor should have access to an y subject records needed to 
verify  the entries on the CRF/eCRF. The investigator agrees to cooperate with the monitor to 
ensure that an y problems detected through an y type of monitoring (central, on site) are resolv ed.
9.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of Gilead may  conduct inspections or audits of the 
clinical study . If the investigator is notified of an inspection by  a regulatory authority  the 
investigato r agrees to notify  the Gilead medical monitor immediately . The investigator agrees to 
provide to representatives of a regulatory  agency  or Gilead access to records, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Discontinuation
Both the S
ponsor and the investigator reserve the right to terminate the study at an y time. Should 
this be necessary , both parties will arrange discontinuation procedures and notify  the appropriate 
regulatory  authorit y(ies), I RBs, and ECs. In te rminating the stud y, Gilead and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 58 28 July 201510. REFERENCES
2202 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum 
creatinine. Nephron 1976;16:31 -41.
3090 Pugh RNH, Murray -Lyon IM, Dawson J L, Pietroni MC, Williams R. Transection 
of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60 (8):646 -9.
7197 U.S. Department of Health and Human Services Food and Drug Administration 
Center for Drug Evaluation and Research (CDER); Center for Biologics 
Evaluation and Research (CBER). Guidance for Industry . Pharmacokinetics in 
Patients with I mpaired Hepatic Function: Study Design, Data Analy sis, and 
Impact on Dosing a nd Labeling.  May , 2003.
8443 Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphrey s WG. In vitro 
inhibition of UDP glucuronosy ltransferases by  atazanavir and other HIV protease 
inhibitors and the relationship of this property  to in vivo bilirubin glucuronidation. 
Drug Metab Dispos 2005;33 (11):1729-39.
17647 Morris DL, O'Neil SP, Devraj RV, Portanova JP, Gilles RW, Gross CJ, et al. 
Acute l ymphoid and gastrointestinal toxicity  induced by  selective p38alpha map 
kinase and map kinase- activated protein kinase -2 (MK2) inhibitors in the dog. 
Toxicol Pathol 2010;38 (4):606
-18.
22804 Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, L acasce A, et 
al. Inhibition of S yk with fostamatinib disodium has significant clinical activity in 
non-Hodgkin ly mphoma and chronic l ymphocy tic leukemia. Blood 2010;115 
(13):2578-85.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 59 28 July 201511. APPENDICES
Appendix 1. Investigator Signature Page
Appendix 2. Management of Clinical an d Laboratory Adverse Events
Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
Appendix 4. GSI Grading Scale for Severity of A dverse Events and Laboratory Abnormalities
Appendix 5. Child -Pugh -Turcotte Score
PPD
PPDEntospletinib 
Protocol GS-US-339-1631 Final 
Gilead Sciences, Inc. Original 
Appendix 1. Investigator Signature Page 
GILEAD SCIENCES, INC. 
333 LAKESIDE DRIVE 
FOSTER CITY, CA 94404 
STUDY ACKNOWLEDGEMENT 
A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Entospletinib 
in Subjects with Normal and Impaired Hepatic Function 
GS-US-339-1631 Original Protocol, 28 July 2015 
This protocol has been approved by Gilead Sciences, Inc. The following signature documents 
this approval. 
Author 
INVESTIGATOR STATEMENT 
I have read the protocol, including all appendices, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described. I will conduct this study as 
outlined herein and will make a reasonable effort to complete the study within the time 
designated. 
I will provide all study personnel under my supervision copies of the protocol and access to all 
information provided by Gilead Sciences, Inc. I will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator Name (Printed) Signature 
Date Site Number 
CONFIDENTIAL Page 60 28 July 2015 
Entospletinib 
Protocol GS-US-339-1631 
Gilead Sciences, Inc. Final 
Original 
Appendix 2. Management of Clinical and Laboratory Adverse Events 
Grade 1 
(Mild) Grade 2 
(Moderate) 
May continue dosing at 
the discretion of the 
Investigator 
CONFIDENTIAL Grade 3 
(Severe) 
.. 
If confirmed, clinically 
significant and related to 
drug, discontinue dosing 
permanently and follow 
until a return to baseline or 
abnormality is otherwise 
explained 
Page 61 I Grade 4 I 
(Possibly life-
Threatening) 
Repeat lab to 
confirm toxicity 
grade 
I 
If confirmed, non-significant or 
not related to study drug, 
dosing may continue at 
discretion of the Investigator 
28 July 2015 
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 62 28 July 2015Appendix 3. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)Definitions
ENTO is contraindicated in pregnancy  as animal studies in rats and rabbits have shown that 
study  drug is teratogenic. Pregnancy must be excluded before the start of treatment with study  
drug and prevented thereafter b y reliable contraceptive methods. Pregn ancy tests will be 
performed regularly  throughout this study  per Table 6-1
. Please refer to the latest version of the 
investigator’s brochure for additional information.
a)Definition of Childbearing Potential
For the purposes of this study , a female born subject is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, unless 
permanentl y sterile or with medically documented ovarian failure.  
Women are considered to be in a postmenopausal stat
e when they  are > 54 years of age with 
cessation of previously  occurring menses for > 12 months without an alternative cause.  In 
addition, women of an y age with amenorrhea of >12 months may  also be considered 
postmenopausal if their follicle stimulating hormone (FSH) level is in the postmenopausal range 
and they  are not using hormonal contraception or hormonal replacement therapy .
Permanent sterilization includes hy sterectomy , bilateral oophorectom y, or bilateral 
salpingectomy  in a female subject of an y age.
b)Definition of Male Fertility
For the purposes of this study , a male born subject is considered to be fertile after the initiation 
of pubert y unless permanently  sterile b y bilateral orchidectom y or medical documentation.
2) Contraception Requirements for Female Subjects
a)Study Drug Effects on Pregnancy and Hormonal Contraception
ENTO is contraindicated in pregnancy  as there is a strong suspicion of human 
teratogenicit y/fetotoxicity  in earl y pregnancy based on non- clinical data. In addition, ENTO has 
insuffic ient data to exclude the possibility  of a clinically  relevant interaction with hormonal 
contraception that results in reduced contraception efficacy ; therefore, contraceptive steroids are 
not recommended as a contraceptive method either solely  or as a part of a contraceptive regimen. 
Please refer to the latest version of the investigator’s brochure for additional information.
b)Contraception Requirements for Female Subjects of Childbearing Potential
The inclusion of female subjects of childbearing potential requires the use of highl y effective 
contraceptive measures.  They  must also not rely  on hormone -containing contraceptives as a 
form of birth control during the stud y.  They must have a negative serum pregnancy test at 
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 63 28 July 2015Screening and a negative pregnancy  test on the Baseline/Day  -1 visit.  Pregnancy  tests will be 
performed on the protocol-specified schedule thereafter.  Female subjects must agree to one of 
the following methods to avoid pregnancy  from Screening until 30 day s from the last dose of 
ENTO:
Comple te abstinence from intercourse of reproductive potential.  Abstinence is an acceptable 
method of contraception only  when it is in line with the subject’s preferred and usual 
lifesty le.
Or
Consistent and correct use of 1 of the following methods of birth control listed below. 
Intrauterine device (IUD) with a failure rate of <1% per year
Tubal sterilization
Essure micro- insert sy stem (provided confirmation of success 3 months after procedure)
Vasectom y in the male partner (provided that the partner is the sole sexual partner and 
had confirmation of surgical success 3 months after procedure)
Female subjects must also refrain from egg donation and in vitro fertilization during treatment 
and unt il at least 30 day s from the last dose of ENTO.
3)
Contraception Requirements for Male Subjects
It istheoreticall y possible that a relevant s ystemic concentration may  be achieved in a female 
partner from exposure of the male subject’s seminal fluid.  Therefo re, male subjects with female 
partners of childbearing potential must use condoms during treatment and until 90 day s from the 
last dose of ENTO.  Additional contraception recommendations should also be considered if the 
female partner is not pregnant.
Male subjects must also refrain from sperm donation during treatment and until at least 90 days 
from the last dose of ENTO.
4) Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (e.g., calendar, 
ovulation, sy mptothermal, post -ovulation methods), withdrawal (coitus interruptus), spermicides 
only, 
and lactational amenorrhea method (LAM).  Female condom and male condom should not 
be used together.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 64 28 July 20155) Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time during 
the study , or if they  become pregnant within 30days of last study  drug dose. Subjects who 
become pregnant or who suspect that they  are pregnant during the stud y must report the 
information to the investigator and discontinue study  drug immediatel y. Subjects whose partner 
has become pregnant or suspects she is pregnant durin g the stud y must report the information to 
the investigator.  Instructions for reporting pregnancy , partner pregnancy , and pregnancy  
outcome are outlined in Section 7.7.2.1.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 65 28 July 2015Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory 
Abnormalities
Version: 18Junel2012
HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hem oglobin
HIV POSITIVE
Adult and Pediatric 
57 Days8.5to10.0 g/dL 
85 to 100 g/L7.5to 8.5g/dL 
75to85g/L6.5 to 7.5g/dL 
65 to 75g/L6.5g/dL
65g/L
HIV NEGATIVE
Adult and Pediatric 
57 Days 10.0 to10.9 g/dL
100to109g/L
OR
Any decrease from 
Baseline
2.5 to 3.5g/dL
25 to 35g/L9.0 to 10.0 g/dL
90 to 100g/L
OR
Any decrease from 
Baseline
3.5 to 4.5g/dL
35 to 45g/L7.0 to 9.0g/dL
70 to 90g/L
OR
Any decrease from 
Baseline
4.5g/dL
45g/L7.0g/dL
70g/L
Infant, 36 –56 Days
(HIV POSITIVE OR
NEGATIVE )8.5 to 9.4 g/dL
85 to 94 g/L7.0 to 8.5g/dL
70 to 85g/L6.0 to 7.0 g/dL
60 to < 70 g/L6.0 g/dL
< 60 g/L
Infant, 22 –35 Days
(HIV POSITIVE OR
NEGATIVE )9.5 to 10.5 g/dL
95 to 105 g/L8.0 to 9.5g/dL
80 to 95g/L7.0 to 8.0g/dL
70 to 80g/L7.0g/dL
70g/L
Infant, 1–21 Days
(HIV POSITIVE OR
NEGATIVE )12.0 to 13.0 g/dL
120 to 130 g/L10.0 to 12.0 g/dL
100 to 120g/L9.0 to 10.0 g/dL
90 to 100g/L9.0g/dL
90g/L
Absolute Neutrophil 
Count 
(ANC)
Adult and Pediatric, 
7Days1000 to1300/mm3750to1000/mm3500to750/mm3500/mm3
1.00 to 1.30 GI/L 0.75 to 1.00 GI/L 0.50 to0.75 GI/L 0.50 GI/L
Infant , 2 –7 Days 1250 to 1500/mm3
1.25 to1.50 GI/L1000 to 1250/mm3
1.00 to< 1.25 GI/L750 to 1000/mm3
0.75 to< 1.00 GI/L750/mm3
< 0.75 GI/L
Infant , 1 Day 4000 to 5000/mm3
4.00 to5.00 GI/L3000 to 4000/mm3
3.00 to < 4.00 GI/L1500 to 3000/mm3
1.50 to< 3.00 GI/L1500/mm3
< 1.50 GI/L
Absolute CD4+ Count
HIV NEGATIVE 
ONLY
Adult and Pediatric 
>13Years300to400/mm3
300to400/μL200to300/mm3
200to 300/μL100to200/mm3
100to200/μL100/mm3
100/μL
Absolute Lymphocyte 
Count
HIV NEGATIVE 
ONLY
Adult and Pediatric 
13Years600 to 650/mm3
0.60 to 0.65 GI/L500 to 600/mm3
0.50 to 0.60 GI/L350 to 500/mm3
0.35 to 0.50 GI/L350/mm3
0.35 GI/L
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 66 28 July 2015HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Platelets 100,000 to 
<125,000/mm3
100to125 GI/L50,000 to 
100,000/mm3
50to 100 GI/L25,000 to 
50,000/mm3
25 to 50 GI/L25,000/mm3
25GI/L
WBCs 2000/mm3to 
2500/mm31,500 to  2,000/mm31000 to 
1,500/mm31000/mm3
2.00 GI/L to 
2.50 GI/L1.50 to 2.00 GI/L 1.00 to 1.50 GI/L1.00 GI/L
Hypofibrinogenemia 100to200mg/dL 75 to 100mg/dL 50to 75mg/d L50mg/d L
1.00 to2.00 g/L 0.75 to 1.00 g/L 0.50 to 0.75 g/L0.50 g/L
Hyperfibrinogenemia ULN to 
600mg/d L600mg/dL — —
ULN  to 6.0 g/L6.0g/L — —
Fibrin Split Product 20 to 40 μg/mL 40to 50μg/mL 50to 60μg/mL 60μg/mL
20 to 40 mg/L 40 to 50 mg/L 50 to 60 mg/L 60mg/L
Prothrombin Time 
(PT)1.00 to 1.25 
ULN1.25 to 1.50 ULN 1.50 to 3.00 
ULN 3.00 ULN 
International 
Normalized Ratio of 
prothrombin time 
(INR)1.1 to 1.5 x ULN >1.5 to 2.0 x ULN >2.0 to 3.0 x ULN >3.0 x ULN
Activated Partial
Thromboplastin Time 
(APTT)1.00 to 1.66
ULN1.66 to 2.33ULN2.33 to 3.00
ULN3.00 ULN
Methemoglobin 5.0to10.0% 10.0 to15.0% 15.0 to20.0% 20.0% 
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 67 28 July 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyponatremia 130 to <LLN mEq/L 125 to130mEq/L 121 to125mEq/L 121 mEq/L
130 to <LLN 
mmol/L125 to130mmol/L 121 to125mmol/L 121 mmol/L
Hypernatremia 146  to 150 mEq/L 150 to 154 mEq/L 154 to 159 mEq/L 159 mEq/L
146  to 150 mmol/L 150 to 154 mmol/L 154 to 159 mmol/L 159 mmol/L
Hypokalemia 3.0 to 3.4 mEq/L 2.5 to3.0mEq/L 2.0 to2.5mEq/L 2.0 mEq/L
3.0 to 3.4 mmol/L 2.5 to3.0mmol/L 2.0 to2.5mmol/L 2.0 mmol/L
Hyperkalemia 5.6 to 6.0 mEq/L 6.0 to 6.5 mEq/L 6.5 to 7.0 mEq/L 7.0 mEq/L
5.6 to 6.0 mmol/L 6.0 to 6.5 mmol/L 6.5 to 7.0 mmol/L 7.0 mmol/L
Hypoglycemia
Adult and Pediatric 55 to 64 mg/dL 40 to55mg/d L 30 to40mg/d L30 mg/dL
1Month 3.03 to 3.58 mmol/L 2.20 to
3.03 mmol/L1.64 to
2.20 mmol/L1.64 mmol/L
Infant,1Month 50 to 54 mg/dL
2.8 to 3.0 mmol/L40 to 50mg/d L
2.2 to 2.8mmol/L30 to 40mg/d L
1.7 to 2.2mmol/L30 mg/dL
1.7 mmol/L
Hyperglycemia, 
Nonfasting 116to 160 mg/dL 160 to 250mg/dL250 to 500 mg/dL500 mg/dL
6.42 to 8.91 mmol/L 8.91 to 
13.90 mmol/L13.90 to 
27.79 mmol/L27.79 mmol/L
Hyperglycemia, 
Fasting110 to 125 mg/dL
6.08 to 6.96 mmol/L>125 to 250 mg/dL
>6.96 to 13.90 
mmol/L>250 to 500 mg/dL
>13.90 to 27.79 
mmol/L>500 mg/dL
>27.79 mmol/L
Hypocalcemia 
(corrected for 
albumin if 
appropriate*)
Adult and Pediatric
7Days7.8 to 8.4  mg/dL 7.0 to7.8 mg/dL 6.1 to7.0mg/dL 6.1mg/d L
1.94 to 2.10 mmol/L 1.74 to1.94 
mmol/L1.51 to1.74 
mmol/L1.51 mmol/L
Infant,7Days 6.5 to 7.5 mg/dL
1.61 to 1.88  mmol/L6.0 to 6.5 mg/dL
1.49 to < 1.61 
mmol/L5.5 to 6.0 mg/dL
1.36 to < 1.49 
mmol/L 5.5 mg/dL
< 1.36 mmol/L
Hypercalcemia 
(corrected for 
albumin if 
appropriate*)
Adultand Pediatric 
7Days>ULN to 11.5 mg/dL 11.5 to 12.5 mg/dL 12.5 to 13.5 mg/dL 13.5 mg/dL
>ULN to 2.88 
mmol/L2.88 to 3.13 
mmol/L3.13 to 3.38 
mmol/L3.38 mmol/L
Infant,7Days 11.5 to 12.4 mg/dL
2.86 to 3.10  mmol/L12.4 to 12.9 mg/dL
> 3.10 to 3.23  
mmol/L12.9 to 13.5 mg/dL
> 3.23 to 3.38  
mmol/L13.5 mg/dL
> 3.38 mmol/L
Hypocalcemia 
(ionized)3.0 mg/dL to LLN 2.5 to < 3.0 mg/dL 2.0 to2.5 mg/dL 2.0 mg/dL
0.74 mmol/L to 
LLN0.62 to0.74 
mmol/L0.49 to0.62 
mmol/L0.49 mmol/L
Hypercalcemia 
(ionized)ULN to 6.0 mg/dL 6.0 to 6.5 mg/dL 6.5 to 7.0 mg/dL 7.0 mg/dL
ULN to 1.50 
mmol/L1.50 to 1.63 
mmol/L1.63 to 1.75 
mmol/L1.75 mmol/L
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 68 28 July 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypomagnesemia 1.40 to  <LLN 
mg/dL
1.2 to <LLN mEq/L1.04 to1.40 mg/dL
0.9 to   1.2 mEq/L0.67 to1.04 mg/dL
0.6 to 0.9 mEq/L0.67 mg/dL
0.6 mEq/L
0.58 to <LLN 
mmol/L0.43 to0.58 
mmol/L0.28 to0.43 
mmol/L0.28 mmol/L
Hypophosphatemia
Adult and Pediatric
14Years2.0 to < LLN mg/dL 1.5 to 2.0 mg/dL 1.0 to 1.5 mg/dL 1.0 mg/dL
0.63  to LLN 
mmol/L0.47 to 0.63 
mmol/L0.31 to 0.47 
mmol/L0.31 mmol/L
Pediatric 1 Year– 14 
Years 3.0 to 3.5 mg/dL
0.96 to 1.14 mmol/L2.5 to 3.0 mg/dL
0.80 to 
<0.96 mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 
mmol/L1.5 mg/dL
<0.47 mmol/L
Pediatric 1Year 3.5 to 4.5 mg/dL
1.12 to 1.46 mmol/L2.5 to 3.5mg/dL
0.80 to 
<1.12 mmol/L1.5 to 2.5 mg/dL
0.47 to < 0.80 
mmol/L1.5 mg/dL
<0.47 mmol/L
Hyperbilirubinemia 
Adult and Pediatric 
>14Days1.0 to 1.5 ULN 1.5 to 2.5 ULN2.5 to 5.0 ULN 5.0 ULN 
Infant, 14Days
(non-hemolytic)NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 to 30.0 mg/dL
> 428 to 513 μmol/L30.0 mg/dL
> 513 μmol/L
Infant, 14Days
(hemolytic)NA NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 mg/dL
> 428 μmol/L
Blood Urea Nitrogen 1.25 to 2.50 ULN 2.50 to 5.00 
ULN 5.00 to 10.00 
ULN 10.00  ULN
Hyperuricemia >ULN to 10.0 mg/dL 10.0 to 12.0 mg/dL 12.0 to 15.0 mg/dL 15.0 mg/dL
>ULN to 597 
μmol/L597 to 716 μmol/L 716 to 895 μmol/L 895 μmol/L
Hypouricemia 1.5 mg/dL to LLN 1.0 to1.5 mg/dL 0.5 to1.0 mg/dL 0.5 mg/dL
87 μmol/L to LLN 57 to87 μmol/L 27 to57 μmol/L 27 μmol/L
Creatinine 1.50 to 2.00 mg/dL 2.00 to 3.00 mg/dL 3.00 to 6.00 mg/dL 6.00 mg/dL
133 to 177 μmol/L 177 to 265 μmol/L 265 to 530 μmol/L 530 μmol/L
Bicarbonate 16.0 mEq/L to
LLN 11.0 to16.0 
mEq/L8.0 to11.0 mEq/L 8.0mEq/L
16.0 mmol/L to
LLN11.0 to16.0 
mmol/L8.0 to11.0 mmol/L 8.0 mmol/L
Triglycerides
(Fasting)NA 500 to 750 mg/dL 750 to 1200 mg/dL 1200 mg/dL
5.64–8.47 mmol/L 8.47–13.55 
mmol/L13.55 mmol/L
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 69 28 July 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
LDL
(Fasting)130 to 160 mg/dL >160 to 190 mg/dL > 190 mg/dL NA
3.35 to 4.15 mmol/L >4.15 to 4.92 
mmol/L>4.92 mmol/L
Pediatric >2 to <18 
years110 to 130 mg/dL >130 to 190 mg/dL > 190 mg/dL NA
2.84 to 3.37 mmol/L >3.37 to  4.92 
mmol/L>4.92 mmol/L
Hypercholesterolemia
(Fasting)200 to 239 mg/dL 239 to 300 mg/dL 300 mg/dL NA
5.16 to 6.19 mmol/L 6.19 to 7.77 
mmol/L7.77 mmol/L
Pediatric 18 Years 170 to 199 mg/dL
4.39 to 5.15 mmol/L199 to 300 mg/dL
5.15 to 7.77 
mmol/L300 mg/dL
7.77 mmol/LNA
Creatine Kinase 3.0 to6.0 ULN 6.0 to10.0 ULN 10.0 to20.0 
ULN20.0 ULN
* Calcium should be corrected for albumin if albumin is < 4.0 g/dL
ENZYMES
Grade 1 Grade 2 Grade 3 Grade 4
AST (SGOT) 1.25 to 2.50 ULN2.50 to 5.00 ULN5.00 to 10.00 
ULN10.00  ULN
ALT (SGPT) 1.25 to 2.50 ULN2.50 to 5.00 ULN5.00 to 10.00 
ULN10.00  ULN
GGT 1.25 to 2.50 ULN2.50 to 5.00 ULN5.00 to 10.00 
ULN10.00  ULN
Alkaline Phosphatase 1.25 to 2.50 ULN2.50 to 5.00 ULN5.00 to 10.00 
ULN10.00  ULN
Total Amylase 1.0 to 1.5 ULN1.5 to 2.0 ULN 2.0 to 5.0 ULN5.0 ULN
Pancreatic Amylase 1.0 to 1.5 ULN1.5 to 2.0 ULN 2.0 to 5.0 ULN5.0 ULN
Lipase 1.0 to 1.5 ULN1.5 to 3.0 ULN 3.0 to 5.0 ULN5.0 ULN
Albumin 3.0 g/dL to LLN
30 g/L to LLN2.0 to 3.0 g/dL
20 to 30 g/L2.0 g/dL
20 g/LNA
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 70 28 July 2015URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Hem aturia (Dipstick) 1 2 3-4+ NA
Hem aturia 
(Quantitative) 
See Note below
                              
Females>ULN -
10RBC/HPF10-75RBC/HPF > 75 RBC/HPF NA
                              
Males6-10 RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
Proteinuria (Dipstick) 1 2–3 4 NA
Proteinuria, 24 Hour 
Collection
Adult and Pediatric 
10 Years200 to999 mg/24 h>999 to 1999 mg/24 h >1999 to3500 
mg/24 h3500 mg/24 h
Pediatric 3 Mo to 
<10Years201 to499 
mg/m2/24h>499 to799 mg/m2/24 
h>799 to1000 
mg/m2/24 h1000 mg/ m2/24 
h
Glycosuria (Dipstick) 1+ 2-3 4 NA
Notes: 
 Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by Covance Laboratory, however for other 
laboratories, toxicity grades will only be assigned to Dipstick Hematuria.
 With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be 
assigned Grade 0.
 If the severity of a clinical AE could fall under either one of two grades (e.g., the severity of an AE could be either Grade 2 
or Grade 3), select the higher of the two grades for the AE.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 71 28 July 2015CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac Arrhythmia 
(general)
(By ECG or physical 
exam)Asymptomatic AND 
No intervention 
indicatedAsymptomatic AND 
Non-urgent medical 
intervention 
indicatedSymptomatic, 
non-life-threatening 
AND Non -urgent 
medical 
intervention 
indicated Life-threatening 
arrhythmia OR 
Urgent intervention 
indicated
Cardiac- ischemia/
InfarctionNA NA Symptomatic 
ischemia (stable 
angina) OR Testing 
consistent with 
ischemia Unstable angina OR 
Acute myocardial 
infarction
Hem orrhage 
(significant acute 
blood loss)NA Symptomatic AND 
No transfusion 
indicatedSymptomatic AND 
Transfusion of 
2units packed 
RBCs (for children 
10cc/kg) 
indicated Life-threatening 
hypotension OR 
Transfusion of 
2units packed 
RBCs indicated (for 
children 10cc/kg) 
indicated
Hypertension 
(withrepeat testing 
atsame visit)140– 159mmH g 
systolic 
OR 
90–99 mmHg 
diastolic159–179 mmHg 
systolic 
OR 
99–109 mmHg 
diastolic179mmHg 
systolic 
OR 
109mmHg 
diastolicLife-threatening 
consequences 
(eg,malignant 
hypertension) OR 
Hospitalization 
(other than ER visit) 
indicated
Pediatric 17Years 
(with repeat testing 
atsame visit)NA 91st–94th percentile 
adjusted for age, 
height, and gender 
(systolic and/or 
diastolic)≥95th percentile 
adjusted for age, 
height, and gender 
(systolic and/or 
diastolic)Life-threatening 
consequences 
(eg,malignant 
hypertension) OR 
Hospitalization 
indicated (other than 
emergency room 
visit)
Hypotension NA Symptomatic, 
corrected with oral 
fluid replacementSymptomatic, IV 
fluids indicatedShock requiring use 
of vasopressors or 
mechanical 
assistance to 
maintain blood 
pressure
Pericardial Effusion Asymptomatic, 
small effusion 
requiring no 
interventionAsymptomatic, 
moderate or larger 
effusion requiring 
no interventionEffusion with 
non-life-threatening 
physiologic 
consequences OR 
Effusion with 
nonurgent 
intervention 
indicatedLife-threatening 
consequences 
(eg,tamponade) OR 
Urgent intervention 
indicated
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 72 28 July 2015CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Prolonged PR Interval PR interval 
0.21 to 0.25 secPR interval
0.25 secType II 2nd degree 
AV block OR 
Ventricular pause 
3.0 secCom plete AV block 
Pediatric 16 Years 1st degree AV block
(PR > normal for 
age and rate)Type I 2nd degree 
AV block Type II 2nd degree 
AV block Com plete AV block
Prolonged QTc Asymptomatic, QTc 
interval 0.45 to 0.47 
sec OR Increase 
interval 0.03 sec 
above baselineAsymptomatic, QTc 
interval 0.48 to 0.49 
sec OR Increase in 
interval 0.03 to 0.05 
sec above baselineAsymptomatic, 
QTc interval 
0.50 sec OR 
Increase in interval 
0.06 sec above 
baselineLife-threatening 
consequences, 
eg,Torsade de 
pointes or other 
associated serious 
ventricular 
dysrhythmia
Pediatric 16Years Asymptomatic, QTc 
interval 0.450 to 
0.464 sec Asymptomatic, QTc 
interval 0.465 to 
0.479 sec Asymptomatic, 
QTc interval 
0.480 sec Life-threatening 
consequences, 
eg,Torsade de 
pointes or other 
associated serious 
ventricular 
dysrhythmia
Thrombosis/Embolism NA Deep vein 
thrombosis AND 
No intervention 
indicated (eg, 
anticoagulation, 
lysis filter, invasive 
procedure) Deep vein 
thrombosis AND 
Intervention 
indicated (eg, 
anticoagulation, 
lysis filter, invasive 
procedure) Embolic event 
(eg, p ulmonary 
embolism, life -
threatening 
thrombus) 
Vasovagal Episode 
(associated w ith a 
procedure of any kind)Present without loss 
of consciousness Present with 
transient loss of 
consciousnessNA NA
Ventricular 
Dysfunction 
(congestive heart 
failure, CHF)NA Asymptomatic 
diagnostic finding 
AND intervention 
indicatedNew  onset with 
symptoms OR 
Worsening 
symptomatic CHFLife-threatening 
CHF
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 73 28 July 2015RESPIRATORY
Grade 1 Grade 2 Grade 3 Grade 4
Bronchospasm 
(acute)FEV1 or peak flow  
reduced to 70% to 
80%FEV1 or peak flow  
50% to 69%FEV1 or peak flow  
25% to 49% Cyanosis OR FEV1 or 
peak flow 25% OR 
Intubation
Dyspnea or 
Respiratory 
DistressDyspnea on exertion 
with no or minimal 
interference with 
usual social & 
functional activities Dyspnea on exertion 
causing greater than 
minimal interference 
with usual social & 
functional activities Dyspnea at rest 
causing inability to 
perform usual 
social & functional 
activities Respiratory failure 
with ventilatory 
support indicated
Pediatric 14 
YearsWheezing OR 
minimal increase in 
respiratory rate for 
ageNasal flaring OR 
Intercostal retractions 
OR Pulse oximetry 
90% to 95%Dyspnea at rest 
causing inability to 
perform usual 
social & functional 
activities OR Pulse 
oximetry 90%Respiratory f ailure 
with ventilatory 
support indicated
OCULAR/VISUAL
Grade 1 Grade 2 Grade 3 Grade 4
Uveitis Asymptomatic but 
detectable on examSymptomatic anterior 
uveitis OR Medical 
intervention indicatedPosterior or pan -
uveitis OR 
Operative 
intervention 
indicatedDisabling visual loss in 
affected eye(s) 
Visual Changes 
(from baseline)Visual changes 
causing no or 
minimal interference 
with usual social & 
functional activitiesVisual changes causing 
greater than minimal 
interference with usual 
social & functional 
activitiesVisual changes 
causing inability to 
perform usual 
social & functional 
activitiesDisabling visual loss in 
affected eye(s)
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 74 28 July 2015SKIN
Grade 1 Grade 2 Grade 3 Grade 4
Alopecia Thinning 
detectable by study 
participant or  
caregiver (for 
disabled adults)Thinning or patchy 
hair loss detectable 
by health care 
providerCom plete hair loss NA
Cutaneous Reaction –
RashLocalized macular 
rash Diffuse macular, 
maculopapular, or 
morbilliform rash 
OR Target lesions Diffuse macular, 
maculopapular, or 
morbilliform rash 
with vesicles or 
limited number of 
bullae OR Superficial 
ulcerations of mucous 
membrane limited to 
one siteExtensive or 
generalized 
bullous lesions OR 
Stevens -Johnson 
syndrome OR 
Ulceration of 
mucous membrane 
involving two or 
more distinct 
mucosal sites OR 
Toxic epidermal 
necrolysis (TEN)
Hyperpigmentation Slight or localized Marked or 
generalizedNA NA
Hypopigmentation Slight or localized Marked or 
generalizedNA NA
Pruritis (itching – no 
skin lesions) 
(See also Injection 
Site Reactions: Pruritis 
associated with 
injection)Itching causing no 
or minimal 
interference with 
usual social & 
functional activitiesItching causing 
greater than minimal 
interference with 
usual social & 
functional activitiesItching causing 
inability to perform 
usual social & 
functional activities NA
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 75 28 July 2015GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Anorexia Loss of appetite 
without decreased 
oral intakeLoss of appetite 
associated with 
decreased oral intake 
without significant 
weight loss Loss of appetite 
associated with 
significant weight 
loss Life-threatening 
consequences OR 
Aggressive 
intervention 
indicated [eg, tube 
feeding or total 
parenteral nutri tion]
Ascites Asymptomatic Symptomatic AND 
Intervention indicated 
(eg, diuretics or 
therapeutic 
paracentesis)Symptomatic despite 
interventionLife-threatening 
consequences
Cholecystitis NA Symptomatic AND 
Medical intervention 
indicatedRadiologic, 
endoscopic, or 
operative 
intervention 
indicatedLife-threatening 
consequences 
(eg,sepsis or 
perforation) 
Constipation NA Persistent constipation 
requiring regular use 
of dietary 
modifications, 
laxatives, or enemas Obstipation with 
manual evacuation 
indicatedLife-threatening 
consequences 
(eg,obstruction)
Diarrhea 
Adult and 
Pediatric 1YearTransient or 
intermittent 
episodes of 
unformed stools 
OR Increase of 
3stools over 
baseline/24 hrPersistent episodes of 
unformed to watery 
stools OR Increase of 
4–6 stools over 
baseline per 24 hrs. Bloody diarrhea OR 
Increase of 
7stools per 
24-hour period OR 
IV fluid replacement 
indicatedLife-threatening 
consequences (eg, 
hypotensive shock)
Pediatric 1Year Liquid stools (more 
unformed than 
usual) but usual 
number of stoolsLiquid stools with 
increased number of 
stools OR Mild 
dehydrationLiquid stools with 
moderate 
dehydrationLiquid stools 
resulting in severe 
dehydration with 
aggressive 
rehydration indicated 
OR Hypotensive 
shock
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 76 28 July 2015GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Dysphagia -
Odynophagia Symptomatic but 
able to eat usual 
dietSymptoms causing 
altered dietary intake 
without medical 
intervention indicatedSymptoms causing 
severely altered 
dietary intake with 
medical intervention 
indicatedLife-threatening 
reduction in oral 
intake
Mucositis/Stomatitis 
(clinical exam)
See also Proctitis, 
Dysphagia -
OdynophagiaErythema of the 
mucosaPatchy 
pseudomembranes or 
ulcerations Confluent 
pseudomembranes or 
ulcerations OR 
Mucosal bleeding 
with minor traumaTissue necrosis OR 
Diffuse spontaneous 
mucosal bleeding 
OR Life -threatening 
consequences (eg, 
aspiration, choking)
Nausea Transient 
(24hours) or 
intermittent nausea 
with no or minimal 
interference with 
oral intakePersistent nausea 
resulting in decreased 
oral intake for 24 –48 
hoursPersistent nausea 
resulting in minimal 
oral intake for 
48hours OR 
Aggressive 
rehydration indicated 
(eg, IV fluids)Life-threatening 
consequences (eg, 
hypotensive shock)
Pancreatitis NA Symptomatic AND 
Hospitalization not 
indicated (other than 
ER visit)Symptomatic AND 
Hospitalization 
indicated (other than 
ER visit)Life-threatening 
consequences (eg, 
sepsis, circulatory 
failure, hemorrhage)
Proctitis 
(functional -
symptomatic)
Also see Mucositis/ 
Stomatitis for 
Clinical ExamRectal discomfort 
AND No 
intervention 
indicatedSymptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities OR Medical 
intervention indicated Symptoms causing 
inability to perform 
usual social/ 
functional activities 
OR Operative 
intervention 
indicated Life-threatening 
consequences 
(eg,perforation)
Vom iting Transient or 
intermittent 
vomiting with no 
or minimal 
interference with 
oral intakeFrequent episodes of 
vomiting with no or 
mild dehydrationPersistent vomiting 
resulting in 
orthostatic 
hypotension OR 
Aggressive 
rehydration indicatedLife-threatening 
consequences (eg, 
hypotensive shock)
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 77 28 July 2015NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Alteration in 
Personality -Behavior 
or in Mood (eg, 
agitation, anxiety, 
depression, mania, 
psychosis)Alteration causing 
no or minimal 
interference with 
usual social & 
functional 
activities Alteration causing 
greater than minimal 
interference with 
usual so cial & 
functional activities Alteration causing 
inability to perform 
usual social & 
functional activities Behavior potentially 
harmful to self or 
others (eg, 
suicidal/homicidal 
ideation or attempt, 
acute psychosis) OR 
Causing inability to 
perform basic 
self-care functions
Altered Mental Status 
For Dementia, see 
Cognitive and 
Behavioral/Attentional 
Disturbance 
(including dementia 
and ADD)Changes causing 
no or minimal 
interference with 
usual social & 
functional 
activitiesMild lethargy or 
somnolence causing 
greater than minimal 
interference with 
usual social & 
functional activitiesConfusion, memory 
impairm ent, 
lethargy, or 
somnolence causing 
inability to perform 
usual social & 
functional activitiesDelirium OR 
obtundation, OR 
coma
Ataxia Asymptomatic 
ataxia detectable 
on exam OR 
Minimal ataxia 
causing no or 
minimal 
interference with 
usual social & 
functional 
activitiesSymptomatic ataxia 
causing greater than 
minimal interference 
with usual social & 
functional activitiesSymptomatic ataxia 
causing inability to 
perform usual social 
& functional 
activities Disabling ataxia 
causing inability to 
perform basic 
self-care functions
Cognitive and 
Behavioral/Attentional 
Disturbance 
(including dementia 
and Attention Deficit 
Disorder) Disability cau sing 
no or minimal 
interference with 
usual social & 
functional 
activities OR 
Specialized 
resources not 
indicatedDisability causing 
greater than minimal 
interference with 
usual social & 
functional activities 
OR Specialized 
resources on part -
time basis indi catedDisability causing 
inability to perform 
usual social & 
functional activities 
OR Specialized 
resources on a full -
time basis indicatedDisability causing 
inability to perform 
basic self -care 
functions OR 
Institutionalization 
indicated
CNS Ischemia
(acute)NA NA Transient ischemic 
attackCerebral vascular 
accident (CVA, 
stroke) with 
neurological deficit 
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 78 28 July 2015NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Developmental delay 
–Pediatric 16 
YearsMild 
developmental 
delay, either motor 
or cognitive, as 
determined by 
comparison with a 
developmental 
screening tool 
appropriate for the 
setting Moderate 
developmental 
delay, either motor 
or cognitive, as 
determined by 
comparison with a 
developmental 
screening tool 
appropriate for the 
setting Severe 
developmental 
delay, either motor 
or cognitive, as 
determined by 
comparison with a 
developmental 
screening tool 
appropriate for the 
setting Developmental 
regression, either 
motor or cognitive, 
as determined b y 
comparison with a 
developmental 
screening tool 
appropriate for the 
setting
Headache Symptoms causing 
no or minimal 
interference with 
usual social & 
functional 
activitiesSymptoms causing 
greater than minimal 
interference with 
usual social & 
functional activitiesSymptoms causing 
inability to perform 
usual social & 
functional activitiesSymptoms causing 
inability to perform 
basic self -care 
functions OR 
Hospitalization 
indicated (other than 
ER visit) OR 
Headache with 
significant 
impairm ent of 
alertness or other 
neurologic function 
Insomnia NA Difficulty sleeping 
causing greater than 
minimal interference 
with usual 
social/functional 
activitiesDifficulty sleeping 
causing inability to 
perform usual social 
& functional 
activitiesDisabling insomnia 
causing inability to 
perform basic 
self-care functions
Neuromuscular 
Weakness 
(including myopathy 
& neuropathy) Asymptomatic 
with decreased 
strength on exam 
OR Minimal 
muscle weak -ness 
causing no or 
minimal 
interference with 
usual social & 
functional 
activitiesMuscle weakness 
causing greater than 
minimal interference 
with usual social & 
functional activitiesMuscle weakness 
causing inability to 
perform usual social 
& functional 
activities Disabling muscle 
weakness causing 
inability to perform 
basic self -care 
functions OR 
Respiratory muscle 
weakness impairing 
ventilation
Neurosensory 
Alteration (including 
paresthesia and 
painful neuropathy)Asymptomatic 
with sensory 
alteration on exam 
or minimal 
paresthesia causing 
no or minimal 
interference with 
usual social &
functional 
activities Sensory alteration or 
paresthesia causing 
greater than minimal 
interference with 
usual social & 
functional activities Sensory alteration or 
paresthesia causing 
inability to perform 
usual social & 
functional activitiesDisabling sen sory 
alteration or 
paresthesia causing 
inability to perform 
basic self -care 
functions
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 79 28 July 2015NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Seizure: (new onset) NA 1 seizure 2–4 seizures Seizures of any kind 
that are prolonged, 
repetitive (eg, status 
epilepticus), or 
difficult to control 
(eg, refractory 
epilepsy)
Seizure: (pre- existing) 
For Worsening of 
Existing Epilepsy the 
Grades Should Be 
Based on an Increase 
from Previous Level 
of Control to Any of 
These LevelsNA Increased frequency 
of pre- existing 
seizures (non -
repetitive) without 
change in seizure 
character OR 
infrequent 
breakthrough 
seizures while on 
stable meds in a 
previously 
controlled seizure 
disorderChange in seizure 
character from 
baseline either in 
duration or quality 
(eg, severity or 
focality) Seizures of any kind 
that are prolong ed, 
repetitive (eg, status 
epilepticus), or 
difficult to control 
(eg, refractory 
epilepsy)
Seizure 
–Pediatric 18 
YearsSeizure, 
generalized onset 
with or without 
secondary 
generalization, 
lasting < 5 minutes 
with < 24hours 
post ictal stateSeizure, generalized 
onset with or 
without secondary 
generalization, 
lasting 5– 20 minutes 
with 
< 24 hours post ictal 
stateSeizure, generalized 
onset with or 
without secondary 
generalization, 
lasting 
> 20 minutes Seizure, generalized 
onset with or 
witho ut secondary 
generalization, 
requiring intubation 
and sedation
Syncope (not 
associated with a 
procedure)NA Present NA NA
Vertigo Vertigo causing no 
or minimal 
interference with 
usual social & 
functional 
activitiesVertigo causing 
greater than minimal 
interference with 
usual social & 
functional activities Vertigo causing 
inability to perform 
usual social & 
functional activitiesDisabling vertigo 
causing inability to 
perform basic 
self-care functions
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 80 28 July 2015MUSCULOSKELETAL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia
See also ArthritisJoint pain causing 
no or minimal 
interference with 
usual social & 
functional activitiesJoint pain causing 
greater than minimal 
interference with usual 
social & functional 
activitiesJoint pain causing 
inability to perform 
usual social & 
functional activitiesDisabling joint pain 
causing inability to 
perform basic 
self-care functions
Arthritis
See also 
ArthralgiaStiffness or joint 
swelling causing no 
or minimal 
interference with 
usual social & 
functional activitiesStiffness or joint 
swelling causing greater 
than minimal 
interference with usual 
social & functional 
activitiesStiffness or joint 
swelling causing 
inability to perform 
usual social & 
functional activi tiesDisabling joint 
stiffness or sw elling 
causing inability to 
perform basic 
self-care functions
Bone Mineral 
LossBMD t -score or z-
score
–2.5 to –1.0 BMD t -score or z-
score–2.5Pathological 
fracture (including 
loss of vertebral 
height)Pathologic fracture 
causing life-
threatening 
consequences 
Pediatric 
21YearsBMD z -score 
–2.5 to –1.0BMD z -score < –2.5 Pathological 
fracture (including 
loss of vertebral 
height)Pathologic fracture 
causing life-
threatening 
consequences 
Myalgia
(non-injection 
site)Muscle pain 
causing no or 
minimal 
interference with 
usual social & 
functional activitiesMuscle pain causing 
greater than minimal 
interference with usual 
social & functional 
activitiesMuscle pain 
causing inability to 
perform usual 
social & functional 
activitiesDisabling muscle 
pain causing inability 
to perform basic 
self-care functions
Osteonecrosis NA Asymptomatic with 
radiographic findings 
AND No operative 
intervention indicatedSymptomatic bone 
pain with 
radiographic 
findings OR 
Operative 
intervention 
indicatedDisabling bone pain 
with radiographic 
findings causing 
inability to perform 
basic self -care 
functions
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 81 28 July 2015SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Acute Systemic 
Allergic Reaction Localized 
urticaria (wheals) 
with no medical 
intervention 
indicatedLocalized urticaria with 
medical intervention 
indicated OR Mild 
angioedema with no 
medical intervention 
indicatedGeneralized urticaria 
OR Angioedema 
with medical 
intervention indicated 
OR Symptomatic 
mild bronchospasmAcute anaphylaxis 
OR Life -threatening 
bronchospasm OR 
laryngeal edema
Chills Symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activitiesSymptoms causing 
greater than minimal 
interference with usual 
social & functional 
activities Symptoms causing 
inability to perform 
usual social & 
functional activitiesNA
Fatigue
MalaiseSymptoms 
causing no or 
minimal 
interference with 
usual social & 
functional 
activitiesSymptoms causing 
greater than minimal 
interference with usual 
social & functional 
activitiesSymptoms causing 
inability to perform 
usual social & 
functional activitiesIncapacitating 
fatigue/malaise 
symptoms causing 
inability to perform 
basic self -care 
functions
Fever 
(nonaxillary)37.7C to 38.6C
99.8F to 101.5F38.7C to 39.3C
101.6F to 102.8F39.4C to 40.5C
102.9F to 104.9F40.5C 
104.9F
Pain-Indicate 
Body  Site
See also Injection 
Site Pain, 
Headache, 
Arthralgia, and 
MyalgiaPain causing no or 
minimal 
interference with 
usual social & 
functional 
activitiesPain causing greater 
than minimal 
interference with usual 
social & functional 
activitiesPain causing inability 
to perform usual 
social & functional 
activitiesDisabling pain 
causing inability to 
perform basic 
self-care functions 
OR Hospitalization 
(other than ER visit) 
indicated
Unintentional 
Weight LossNA 5% to 9% loss in body 
weight from baseline10% to 19% loss in 
body weight from 
baseline20% loss in body 
weight from baseline 
OR  Aggressive 
intervention indicated 
[eg, tube feeding or 
total parenteral 
nutrition]
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 82 28 July 2015INJECTION SITE REACTION
Grade 1 Grade 2 Grade 3 Grade 4
Injection Site Pain 
(pain w ithout 
touching)
Or Tenderness 
(pain when area is 
touched) Pain/tenderness 
causing no or 
minimal limitation 
of use of limbPain/tenderness 
limiting use of limb 
OR Pain/tenderness 
causing greater than 
minimal interference 
with usual social & 
functional activitiesPain/tenderness 
causing inability to 
perform usual 
social & functional 
activitiesPain/tenderness 
causing inability to 
perform basi c self -care 
function OR 
Hospitalization (other 
than ER visit) 
indicated for 
management of 
pain/tenderness
Injection Site 
Reaction 
(Localized), 
15YearsErythema OR 
Induration
of 55cm to 
99cm (or 2581 
cm2)Erythema OR 
Induration OR 
Edema 9cm any 
diam eter (or 
81cm2)Ulceration OR 
Secondary infection 
OR Phlebitis OR 
Sterile abscess OR 
DrainageNecrosis (involving 
dermis and deeper 
tissue)
Pediatric 
15YearsErythem a OR 
Induration OR 
Edema present 
but 2.5cm 
diameterErythem a OR 
Induration OR 
Edema > 2.5cm 
diameter but < 50% 
surface area of the 
extremity segment 
(eg, upper 
arm/thigh)Erythem a OR 
Induration OR 
Edema involving 
50% surface 
area of the 
extremity segment 
(eg, upper 
arm/thigh) OR 
Ulceration OR 
Secondary 
infection OR 
Phlebitis OR 
Sterile abscess OR 
DrainageNecrosis (involving 
dermis and deeper 
tissue)
Pruritis Associated 
with Injection 
See also Skin: 
Pruritis (itching —
no skin lesions)Itching localized to 
injection site AND 
Relieved 
spontaneously or 
with 48h 
treatment Itching beyond the 
injection site but not 
generalized OR 
Itching localized to 
injection site 
requiring 48h 
treatment Generalized itching 
causing inability to 
perform usual 
social & functional 
activitiesNA
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 83 28 July 2015ENDOCRINE/METABOLIC
Grade1 Grade 2 Grade 3 Grade 4
Lipodystrophy 
(eg, back of neck, 
breasts, abdomen)Detectable by 
study participant 
or caregiver (for 
young children 
and disabled 
adults)Detectable on physical 
exam by health care 
providerDisfiguring OR 
Obvious changes on 
casual visual 
inspectionNA
Diabetes Mellitus NA New  onset without need 
to initiate medication 
OR Modification of 
current meds to regain 
glucose controlNew  onset with 
initiation of indicated 
med OR Diabetes 
uncontrolled despite 
treatment 
modificationLife-threatening 
consequences 
(eg,ketoacidosis, 
hyperosmolar 
non-ketotic coma) 
Gynecomastia Detectable by 
study participant 
or caregiver (for 
young children 
and disabled 
adults)Detectable on physical 
exam by health care 
providerDisfiguring OR 
Obvious on casual 
visual inspectionNA
Hyperthyroidism Asymptomatic Symptomatic causing 
greater than minimal 
interference with usual 
social & functional 
activities OR Thyroid 
suppression therapy 
indicatedSymptoms causing 
inability to perform 
usual social & 
functional activities 
OR Uncontrolled 
despite treatment 
modification Life-threatening 
consequences 
(eg,thyroid storm)
Hypothyroidism Asymptomatic Symptomatic causing 
greater than minimal 
interference with usual 
social & functional 
activities OR Thyroid 
replacement therapy 
indicatedSymptoms causing 
inability to perform 
usual social & 
functional activities 
OR Uncontrolled 
despite treatment 
modification Life-threatening 
consequences (eg, 
myxedema coma)
Lipoatrophy (eg, 
fat loss from the 
face, extremities , 
buttocks)Detectable by 
study participant 
or caregiver (for 
young children 
and disabled 
adults)Detectable on physical 
exam by health care 
providerDisfiguring OR 
Obvious on casual 
visual inspectionNA
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 84 28 July 2015GENITOURINARY
Grade 1 Grade 2 Grade 3 Grade 4
Intermenstrual 
Bleeding (IMB)Spotting observed by 
participant OR 
Minimal blood 
observed during 
clinical or colposcopic 
examIntermenstrual 
bleeding not greater 
in duration or amount 
than usual menstrual 
cycleIntermenstrual 
bleeding greater in 
duration or amount 
than usual menstrual 
cycleHem orrhage with 
life-threatening 
hypotension OR 
Operative 
intervention 
indicated
Urinary Tract 
obstruction (eg, 
stone)NA Signs or symptoms of 
urinary tract 
obstruction without 
hydronephrosis or 
renal dysfunctionSigns or symptoms of 
urinary tract 
obstruction with 
hydronephrosis or 
renal dysfunctionObstruction causing 
life-threatening 
consequences
INFECTION
Grade 1 Grade 2 Grade 3 Grade 4
Infection (any 
other than HIV 
infection)Localized, no systemic 
antiμbial treatment 
indicated AND 
Symptoms causing no 
or minimal 
interference with usual 
social & functional 
activitiesSystemic antiμbial 
treatment indicated 
OR Symptoms 
causing greater than 
minimal interference 
with usual social & 
functional activitiesSystemic an tiμbial 
treatment indicated 
AND Symptoms 
causing inability to 
perform usual social & 
functional activities 
OR Operative 
intervention (other 
than simple incision 
and drainage) indicatedLife-threatening 
consequences 
(eg,septic shock)
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Usual Social & Functional Activities: Adaptive tasks and desirable activities, such as going to work, shopping, cooking, use of 
transportation, pursuing a hobby, etc.
Entospletinib
Protocol GS -US-339-1631 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page 85 28 July 2015Appendix 5. Child -Pugh-Turcotte Score
Child-Pugh dassification of severity of liver disease 
Parameter Points assigned 
1 2 3 
Ascites Absent Slight Moderate 
Bilirubin <2 mg/dl 2-3 mg/dl (34.2 >3 mg/dl 
(<34.2 to 51.3 (>51.3 
micromolfliter} micromoljliter) micromolfliter) 
Albumin >3.5 g/dl (35 ,2.8-3.5 g/dl (28 I <2.8 g/dl, <28 
gjliter) to 35 g/liter) gfliter) 
Prothrombin time 
Seconds over <4 4-6 I >6 control 
INR <1.7 1.7-2.3 >2.3 
Encephalopathy None Grade 1-2 Grade 3·4 
Modified Child-Pugh dasslflcatlon of the severity of liver disease 
according to the degree of asdtes, the plasma concentrations 
of bilirubin and albumin, the prothrombin time, and the degree 
of encephalopathy. A total score of 5· 6 is considered grade A 
(well-compensated disease); 7-9 Is grade 8 (significant 
functional compromise); and 10·15 Is grade C (decompensated 
disease). These grades correlate with one-and two-year 
patient survival: grade A -100 and 85 percent; grade B -80 
and 60 percent; and grade C -45 and 35 percent. 